1
|
Lane J, Langdahl B, Stone M, Kurth A, Oates M, Timoshanko J, Wang Z, Libanati C, Cosman F. Romosozumab in patients who experienced an on-study fracture: post hoc analyses of the FRAME and ARCH phase 3 trials. Osteoporos Int 2024:10.1007/s00198-024-07049-w. [PMID: 38573517 DOI: 10.1007/s00198-024-07049-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/20/2023] [Accepted: 02/28/2024] [Indexed: 04/05/2024]
Abstract
Post hoc analysis of FRAME and ARCH revealed that on-study nonvertebral and vertebral fractures by Month 12 were less common in women initially treated with romosozumab versus placebo or alendronate. Recurrent fracture risk was also lower in romosozumab‑treated patients, and there were no fracture‑related complications. Results support continuing romosozumab treatment post‑fracture. PURPOSE Post hoc analysis evaluating efficacy and safety of romosozumab, administered in the immediate post‑fracture period, in the FRAME and ARCH phase 3 trials. METHODS In FRAME (NCT01575834) and ARCH (NCT01631214), postmenopausal women with osteoporosis were randomized 1:1 to romosozumab 210 mg monthly or comparator (FRAME, placebo; ARCH, alendronate 70 mg weekly) for 12 months, followed by antiresorptive therapy (FRAME, denosumab; ARCH, alendronate). In patients who experienced on-study nonvertebral or new/worsening vertebral fracture by Month 12, we report the following: fracture and treatment‑emergent adverse event (TEAE) incidence through 36 months, bone mineral density changes (BMD), and romosozumab timing. Due to the sample sizes employed, meaningful statistical comparisons between treatments were not possible. RESULTS Incidence of on-study nonvertebral and vertebral fractures by Month 12 was numerically lower in romosozumab- versus comparator-treated patients (FRAME, 1.6% and 0.5% versus 2.1% and 1.6%; ARCH, 3.4% and 3.3% versus 4.6% and 4.9%, respectively). In those who experienced on-study nonvertebral fracture by Month 12, recurrent nonvertebral and subsequent vertebral fracture incidences were numerically lower in patients initially treated with romosozumab versus comparator (FRAME, 3.6% [2/56] and 1.8% [1/56] versus 9.2% [7/76] and 3.9% [3/76]; ARCH, 10.0% [7/70] and 5.7% [4/70] versus 12.6% [12/95] and 8.4% [8/95], respectively). Among those with on-study vertebral fracture by Month 12, recurrent vertebral and subsequent nonvertebral fracture incidences were numerically lower with romosozumab versus comparator (FRAME, 0.0% [0/17] and 0.0% [0/17] versus 11.9% [7/59] and 8.5% [5/59]; ARCH, 9.0% [6/67] and 7.5% [5/67] versus 15.0% [15/100] and 16.0% [16/100], respectively). In patients with fracture by Month 12, no fracture‑related complications were reported in romosozumab-treated patients. BMD gains were numerically greater with romosozumab than comparators. CONCLUSION Data suggest support for the efficacy and safety of continuing romosozumab treatment following fracture. TRIAL REGISTRATIONS NCT01575834; NCT01631214.
Collapse
Affiliation(s)
- J Lane
- HSS Ambulatory Care Center, New York, NY, USA
| | - B Langdahl
- Aarhus University Hospital, Aarhus, Denmark
| | - M Stone
- University Hospital Llandough, Cardiff and Vale University Health Board, Cardiff, Wales
| | - A Kurth
- Department of Orthopaedic and Trauma Surgery Center for Orthopaedic and Trauma Surgery, Marienhaus Klinikum Mainz, Major Teaching Hospital, University Medicine Mainz, Mainz, Germany
| | - M Oates
- Amgen Inc, Thousand Oaks, CA, USA
| | | | - Z Wang
- Amgen Inc, Thousand Oaks, CA, USA
| | | | - F Cosman
- Columbia University, New York, NY, USA.
| |
Collapse
|
2
|
Riesle-Sbarbaro SA, Wibbelt G, Düx A, Kouakou V, Bokelmann M, Hansen-Kant K, Kirchoff N, Laue M, Kromarek N, Lander A, Vogel U, Wahlbrink A, Wozniak DM, Scott DP, Prescott JB, Schaade L, Couacy-Hymann E, Kurth A. Selective replication and vertical transmission of Ebola virus in experimentally infected Angolan free-tailed bats. Nat Commun 2024; 15:925. [PMID: 38297087 PMCID: PMC10830451 DOI: 10.1038/s41467-024-45231-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2023] [Accepted: 01/16/2024] [Indexed: 02/02/2024] Open
Abstract
The natural reservoir of Ebola virus (EBOV), agent of a zoonosis burdening several African countries, remains unidentified, albeit evidence points towards bats. In contrast, the ecology of the related Marburg virus is much better understood; with experimental infections of bats being instrumental for understanding reservoir-pathogen interactions. Experiments have focused on elucidating reservoir competence, infection kinetics and specifically horizontal transmission, although, vertical transmission plays a key role in many viral enzootic cycles. Herein, we investigate the permissiveness of Angolan free-tailed bats (AFBs), known to harbour Bombali virus, to other filoviruses: Ebola, Marburg, Taï Forest and Reston viruses. We demonstrate that only the bats inoculated with EBOV show high and disseminated viral replication and infectious virus shedding, without clinical disease, while the other filoviruses fail to establish productive infections. Notably, we evidence placental-specific tissue tropism and a unique ability of EBOV to traverse the placenta, infect and persist in foetal tissues of AFBs, which results in distinct genetic signatures of adaptive evolution. These findings not only demonstrate plausible routes of horizontal and vertical transmission in these bats, which are expectant of reservoir hosts, but may also reveal an ancillary transmission mechanism, potentially required for the maintenance of EBOV in small reservoir populations.
Collapse
Affiliation(s)
- S A Riesle-Sbarbaro
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - G Wibbelt
- Leibniz Institute for Zoo and Wildlife Research, Berlin, Germany
| | - A Düx
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- Helmholtz Institute for One Health, Greifswald, Germany
| | - V Kouakou
- LANADA, Laboratoire National d'Appui au Développement Agricole, Bingerville, Côte d'Ivoire
| | - M Bokelmann
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - K Hansen-Kant
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - N Kirchoff
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - M Laue
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - N Kromarek
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - A Lander
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - U Vogel
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - A Wahlbrink
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - D M Wozniak
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany
| | - D P Scott
- Rocky Mountain Laboratories, National Institutes of Health, Hamilton, MT, USA
| | - J B Prescott
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - L Schaade
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - E Couacy-Hymann
- LANADA, Laboratoire National d'Appui au Développement Agricole, Bingerville, Côte d'Ivoire
- Centre National de Recherches Agronomiques, LIRED, Abidjan, Côte d'Ivoire
| | - A Kurth
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
| |
Collapse
|
3
|
Riesle-Sbarbaro SA, Kirchoff N, Hansen-Kant K, Stern A, Kurth A, Prescott JB. Human-to-Human Transmission of Andes Virus Modeled in Syrian Hamsters. Emerg Infect Dis 2023; 29:2159-2163. [PMID: 37735788 PMCID: PMC10521624 DOI: 10.3201/eid2910.230544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/23/2023] Open
Abstract
Several occurrences of human-to-human transmission of Andes virus, an etiological agent of hantavirus cardiopulmonary syndrome, are documented. Syrian hamsters consistently model human hantavirus cardiopulmonary syndrome, yet neither transmission nor shedding has been investigated. We demonstrate horizontal virus transmission and show that Andes virus is shed efficiently from both inoculated and contact-infected hamsters.
Collapse
|
4
|
Fuggle N, Al-Daghri N, Bock O, Branco J, Bruyère O, Casado E, Cavalier E, Cortet B, de Wit M, Giusti A, Halbout P, Harvey NC, Hiligsmann M, Kaufman JM, Kurth A, Maggi S, Matijevic R, Minisola S, Palacios S, Radermecker RP, Thomasius F, Tuzun S, Veronese N, Kanis JA, Reginster JY, Rizzoli R, Cooper C. Correction: Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin Exp Res 2023; 35:1375-1376. [PMID: 36595210 PMCID: PMC10200775 DOI: 10.1007/s40520-022-02319-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Affiliation(s)
- Nicholas Fuggle
- MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Nasser Al-Daghri
- Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Olivier Bock
- Department of Osteoporosis, Inselspital-Bern University Hospital, University of Bern, Bern, Switzerland
- International Osteoporosis Foundation, Nyon, Switzerland
| | - Jaime Branco
- Centro Hospitalar de Lisboa Ocidental-Hospital Egas Moniz, CEDOC/NOVA Medical School, Nova University of Lisbon, Lisbon, Portugal
| | - Olivier Bruyère
- Division of Public Health, Epidemiology and Health Economics, WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liege, Belgium
| | - Enrique Casado
- Department of Rheumatology, University Hospital Parc Taulí, I3PT Research Institute (UAB), Sabadell, Barcelona, Spain
| | - Etienne Cavalier
- Department of Clinical Chemistry, University of Liège, CIRM, CHU Sart-Tilman, 4000, Liège, Belgium
| | - Bernard Cortet
- Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France
| | - Maarten de Wit
- Department of Medical Humanities, Amsterdam University Medical Centre, Amsterdam, The Netherlands
| | - Andrea Giusti
- Metabolic Bone Diseases Unit and Fracture Liaison Service, Rheumatology Unit, Department of Medical Specialties, Local Health Trust 3, Via Missolungi 14, 16147, Genoa, Italy
| | | | - Nicholas C Harvey
- MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK
- NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, UK
| | - Mickaël Hiligsmann
- Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands
| | - Jean-Marc Kaufman
- Department of Endocrinology, Ghent University Hospital, 9000, Ghent, Belgium
| | - Andreas Kurth
- Department of Orthopaedic and Trauma Surgery, Community Clinics Middle Rhine, Campus Kemperhof, Koblenz, Germany
| | - Stefania Maggi
- Institute of Neuroscience, Aging Branch, CNR, Padua, Italy
| | - Radmila Matijevic
- Faculty of Medicine, Clinic for Orthopedic Surgery and Traumatology, Clinical Center of Vojvodina, University of Novi Sad, Novi Sad, Serbia
| | - Salvatore Minisola
- Department of Clinical, Internal, Anaesthesiology, and Cardiovascular Sciences, Sapienza University of Rome, 00185, Rome, Italy
| | | | - Régis Pierre Radermecker
- Department of Diabetes, Nutrition and Metabolic Disorders, Clinical Pharmacology, University of Liège, CHU de Liège, Liège, Belgium
| | | | - Sansin Tuzun
- Department of Physical Medicine and Rehabilitation, Cerrahpaşa Medical Faculty, Istanbul University Cerrahpaşa, Istanbul, Turkey
| | - Nicola Veronese
- Department of Internal Medicine, Geriatrics Section, University of Palermo, Palermo, Italy
| | - John A Kanis
- Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia
- Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
| | - Jean-Yves Reginster
- Centro Hospitalar de Lisboa Ocidental-Hospital Egas Moniz, CEDOC/NOVA Medical School, Nova University of Lisbon, Lisbon, Portugal
| | - René Rizzoli
- Department of Osteoporosis, Inselspital-Bern University Hospital, University of Bern, Bern, Switzerland
| | - Cyrus Cooper
- MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK.
- Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
- NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
| |
Collapse
|
5
|
Händel MN, Cardoso I, von Bülow C, Rohde JF, Ussing A, Nielsen SM, Christensen R, Body JJ, Brandi ML, Diez-Perez A, Hadji P, Javaid MK, Lems WF, Nogues X, Roux C, Minisola S, Kurth A, Thomas T, Prieto-Alhambra D, Ferrari SL, Langdahl B, Abrahamsen B. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ 2023; 381:e068033. [PMID: 37130601 PMCID: PMC10152340 DOI: 10.1136/bmj-2021-068033] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
OBJECTIVE To review the comparative effectiveness of osteoporosis treatments, including the bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in postmenopausal women, and to characterise the effect of antiosteoporosis drug treatments on the risk of fractures according to baseline risk factors. DESIGN Systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. DATA SOURCES Medline, Embase, and Cochrane Library to identify randomised controlled trials published between 1 January 1996 and 24 November 2021 that examined the effect of bisphosphonates, denosumab, selective oestrogen receptor modulators, parathyroid hormone receptor agonists, and romosozumab compared with placebo or active comparator. ELIGIBILITY CRITERIA FOR SELECTING STUDIES Randomised controlled trials that included non-Asian postmenopausal women with no restriction on age, when interventions looked at bone quality in a broad perspective. The primary outcome was clinical fractures. Secondary outcomes were vertebral, non-vertebral, hip, and major osteoporotic fractures, all cause mortality, adverse events, and serious cardiovascular adverse events. RESULTS The results were based on 69 trials (>80 000 patients). For clinical fractures, synthesis of the results showed a protective effect of bisphosphonates, parathyroid hormone receptor agonists, and romosozumab compared with placebo. Compared with parathyroid hormone receptor agonists, bisphosphonates were less effective in reducing clinical fractures (odds ratio 1.49, 95% confidence interval 1.12 to 2.00). Compared with parathyroid hormone receptor agonists and romosozumab, denosumab was less effective in reducing clinical fractures (odds ratio 1.85, 1.18 to 2.92 for denosumab v parathyroid hormone receptor agonists and 1.56, 1.02 to 2.39 for denosumab v romosozumab). An effect of all treatments on vertebral fractures compared with placebo was found. In the active treatment comparisons, denosumab, parathyroid hormone receptor agonists, and romosozumab were more effective than oral bisphosphonates in preventing vertebral fractures. The effect of all treatments was unaffected by baseline risk indicators, except for antiresorptive treatments that showed a greater reduction of clinical fractures compared with placebo with increasing mean age (number of studies=17; β=0.98, 95% confidence interval 0.96 to 0.99). No harm outcomes were seen. The certainty in the effect estimates was moderate to low for all individual outcomes, mainly because of limitations in reporting, nominally indicating a serious risk of bias and imprecision. CONCLUSIONS The evidence indicated a benefit of a range of treatments for osteoporosis in postmenopausal women for clinical and vertebral fractures. Bone anabolic treatments were more effective than bisphosphonates in the prevention of clinical and vertebral fractures, irrespective of baseline risk indicators. Hence this analysis provided no clinical evidence for restricting the use of anabolic treatment to patients with a very high risk of fractures. SYSTEMATIC REVIEW REGISTRATION PROSPERO CRD42019128391.
Collapse
Affiliation(s)
- Mina Nicole Händel
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Department of Clinical Research, Odense Patient Data Explorative Network, University of Southern Denmark, Odense, Denmark
| | - Isabel Cardoso
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
| | - Cecilie von Bülow
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Occupational Science, User Perspectives and Community-Based Interventions, Department of Public Health, University of Southern Denmark, Odense C, Denmark
| | - Jeanett Friis Rohde
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
| | - Anja Ussing
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
| | - Sabrina Mai Nielsen
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
| | - Robin Christensen
- Parker Institute, Bispebjerg and Frederiksberg Hospital, 2000 Frederiksberg, Denmark
- Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark
| | - Jean-Jacques Body
- Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | | | - Adolfo Diez-Perez
- Department of Internal Medicine, Institut Hospital del Mar of Medical Investigation, Autonomous University of Barcelona and CIBERFES (Frailty and Healthy Aging Research Network), Instituto Carlos III, Barcelona, Spain
| | - Peyman Hadji
- Frankfurt Centre of Bone Health, Frankfurt and Philipps-University of Marburg, Marburg, Germany
| | - Muhammad Kassim Javaid
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | | | - Xavier Nogues
- IMIM (Hospital del Mar Medical Research Institute), Parc de Salut Mar, Pompeu Fabra University, Barcelona, Spain
| | - Christian Roux
- INSERM U 1153, Hospital Paris-Centre, University of Paris, Paris, France
| | - Salvatore Minisola
- Department of Clinical, Internal, Anaesthesiologic, and Cardiovascular Sciences, Rome University, Rome, Italy
| | - Andreas Kurth
- Department of Orthopaedic and Trauma Surgery, Marienhaus Klinikum Mainz, Major Teaching Hospital, University Medicine Mainz, Mainz, Germany
| | - Thierry Thomas
- Université Jean Monnet Saint-Étienne, CHU de Saint-Etienne, Rheumatology Department, INSERM U1059, F-42023, Saint-Etienne, France
| | - Daniel Prieto-Alhambra
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
- Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands
| | | | - Bente Langdahl
- Departments of Clinical Medicine and of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark
| | - Bo Abrahamsen
- Department of Clinical Research, Odense Patient Data Explorative Network, University of Southern Denmark, Odense, Denmark
- Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK
- Department of Medicine, Holbæk Hospital, Holbæk, Denmark
| |
Collapse
|
6
|
Tarantino U, Cariati I, Greggi C, Iundusi R, Gasbarra E, Iolascon G, Kurth A, Akesson KE, Bouxsein M, Tranquilli Leali P, Civinini R, Falez F, Brandi ML. Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review. Osteoporos Int 2022; 33:2467-2478. [PMID: 35851407 DOI: 10.1007/s00198-022-06482-z] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/03/2021] [Accepted: 06/23/2022] [Indexed: 10/17/2022]
Abstract
Osteoporotic fractures are one of the major problems facing healthcare systems worldwide. Undoubtedly, fragility fractures of the hip represent a far greater burden in terms of morbidity, mortality, and healthcare costs than other fracture sites. However, despite the significant impact on the health and quality of life of older adults, there is a general lack of awareness of osteoporosis, which results in suboptimal care. In fact, most high-risk individuals are never identified and do not receive adequate treatment, leading to further fragility fractures and worsening health status. Furthermore, considering the substantial treatment gap and the proven cost-effectiveness of fracture prevention programs such as Fracture Liaison Services, urgent action is needed to ensure that all individuals at high risk of fragility fracture are adequately assessed and treated. Based on this evidence, the aim of our review was to (i) provide an overview and comparison of the burden and management of fragility fractures, highlighting the main gaps, and (ii) highlight the importance of using alternative approaches, both surgical and non-surgical, with the aim of implementing early prevention of osteoporotic fractures and improving the management of osteoporotic patients at imminent and/or very high risk of fracture.
Collapse
Affiliation(s)
- Umberto Tarantino
- Department of Clinical Sciences and Translational Medicine, "Tor Vergata" University of Rome, Via Montpellier 1, 00133, Rome, Italy
- Department of Orthopaedics and Traumatology, "Policlinico Tor Vergata" Foundation, Viale Oxford 1, 00133, Rome, Italy
| | - Ida Cariati
- Department of Clinical Sciences and Translational Medicine, "Tor Vergata" University of Rome, Via Montpellier 1, 00133, Rome, Italy
- PhD in Medical-Surgical Biotechnologies and Translational Medicine, "Tor Vergata" University of Rome, Via Montpellier 1, 00133, Rome, Italy
| | - Chiara Greggi
- Department of Clinical Sciences and Translational Medicine, "Tor Vergata" University of Rome, Via Montpellier 1, 00133, Rome, Italy
- PhD in Medical-Surgical Biotechnologies and Translational Medicine, "Tor Vergata" University of Rome, Via Montpellier 1, 00133, Rome, Italy
| | - Riccardo Iundusi
- Department of Orthopaedics and Traumatology, "Policlinico Tor Vergata" Foundation, Viale Oxford 1, 00133, Rome, Italy
| | - Elena Gasbarra
- Department of Orthopaedics and Traumatology, "Policlinico Tor Vergata" Foundation, Viale Oxford 1, 00133, Rome, Italy
| | - Giovanni Iolascon
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Caserta, Italy
| | - Andreas Kurth
- Department of Orthopaedic and Trauma Surgery, Community Clinics Middle Rhine, Campus Kemperhof, Koblenz, Germany
| | - Kristina E Akesson
- Department of Clinical Sciences Malmö, Lund University and Department of Orthopedics, Skane University Hospital, Malmö, Sweden
| | - Mary Bouxsein
- Department of Orthopedic Surgery, Center for Advanced Orthopedic Studies, Harvard Medical School, BIDMC, Boston, MA, USA
| | | | - Roberto Civinini
- Department of Surgical Science, University of Florence, Florence, Italy
| | - Francesco Falez
- Orthopaedic and Traumatology Department, S. Spirito Hospital, Rome, Italy
| | | |
Collapse
|
7
|
Fuggle N, Al-Daghri N, Bock O, Branco J, Bruyère O, Casado E, Cavalier E, Cortet B, de Wit M, Giusti A, Halbout P, Harvey NC, Hiligsmann M, Kaufman JM, Kurth A, Maggi S, Matijevic R, Minisola S, Palacios S, Radermecker RP, Thomasius F, Tuzun S, Veronese N, Kanis JA, Reginster JY, Rizzoli R, Cooper C. Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin Exp Res 2022; 34:2625-2634. [PMID: 36331798 PMCID: PMC9675642 DOI: 10.1007/s40520-022-02272-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Accepted: 10/03/2022] [Indexed: 11/06/2022]
Abstract
Oral bisphosphonates are a key intervention in the treatment of osteoporosis and in reducing the risk of fragility fractures. Their use is supported by over 3 decades of evidence; however, patient adherence to oral bisphosphonates remains poor in part due to complex dosing instructions and adverse events, including upper gastrointestinal symptoms. This problem has led to the development of novel oral bisphosphonate formulations. Buffered, effervescent alendronate is dissolved in water and so seeks to reduce upper gastro-intestinal adverse events, and gastro-resistant risedronate aims to reduce the complexity of dosing procedure (e.g. fasting prior to consumption) whilst still maintaining the efficacy of fracture risk reduction. Clinical trials and real-world data have been employed to demonstrate some benefits in terms of reduced upper gastro-intestinal adverse events, adherence, persistence and health economic outcomes. This report describes the result of an ESCEO (European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis) expert working group, which explores where oral bisphosphonates sit in current clinical practice guidelines, review their risk-benefit profile and the consequences of poor adherence before exploring novel oral bisphosphonate formulations and their potential clinical and health economic impact. Further research is required but there are signs that these novel, oral bisphosphonate formulations may lead to improved tolerance of oral bisphosphonates and thus, improved adherence and fracture outcomes.
Collapse
Affiliation(s)
- Nicholas Fuggle
- MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK
| | - Nasser Al-Daghri
- Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Olivier Bock
- Department of Osteoporosis, Inselspital-Bern University Hospital, University of Bern, Bern, Switzerland
- International Osteoporosis Foundation, Nyon, Switzerland
| | - Jaime Branco
- Centro Hospitalar de Lisboa Ocidental-Hospital Egas Moniz, CEDOC/NOVA Medical School, Nova University of Lisbon, Lisbon, Portugal
| | - Olivier Bruyère
- Division of Public Health, Epidemiology and Health Economics, WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, University of Liège, Avenue Hippocrate 13, CHU B23, 4000, Liege, Belgium
| | - Enrique Casado
- Department of Rheumatology, University Hospital Parc Taulí, I3PT Research Institute (UAB), Sabadell, Barcelona, Spain
| | - Etienne Cavalier
- Department of Clinical Chemistry, University of Liège, CIRM, CHU Sart-Tilman, 4000, Liège, Belgium
| | - Bernard Cortet
- Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France
| | - Maarten de Wit
- Department of Medical Humanities, Amsterdam University Medical Centre, Amsterdam, The Netherlands
| | - Andrea Giusti
- Metabolic Bone Diseases Unit and Fracture Liaison Service, Rheumatology Unit, Department of Medical Specialties, Local Health Trust 3, Via Missolungi 14, 16147, Genoa, Italy
| | | | - Nicholas C Harvey
- MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK
- NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, UK
| | - Mickaël Hiligsmann
- Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, The Netherlands
| | - Jean-Marc Kaufman
- Department of Endocrinology, Ghent University Hospital, 9000, Ghent, Belgium
| | - Andreas Kurth
- Department of Orthopaedic and Trauma Surgery, Community Clinics Middle Rhine, Campus Kemperhof, Koblenz, Germany
| | - Stefania Maggi
- Institute of Neuroscience, Aging Branch, CNR, Padua, Italy
| | - Radmila Matijevic
- Faculty of Medicine, Clinic for Orthopedic Surgery and Traumatology, Clinical Center of Vojvodina, University of Novi Sad, Novi Sad, Serbia
| | - Salvatore Minisola
- Department of Clinical, Internal, Anaesthesiology, and Cardiovascular Sciences, Sapienza University of Rome, 00185, Rome, Italy
| | | | - Régis Pierre Radermecker
- Department of Diabetes, Nutrition and Metabolic Disorders, Clinical Pharmacology, University of Liège, CHU de Liège, Liège, Belgium
| | | | - Sansin Tuzun
- Department of Physical Medicine and Rehabilitation, Cerrahpaşa Medical Faculty, Istanbul University Cerrahpaşa, Istanbul, Turkey
| | - Nicola Veronese
- Department of Internal Medicine, Geriatrics Section, University of Palermo, Palermo, Italy
| | - John A Kanis
- Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia
- Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK
| | - Jean-Yves Reginster
- Centro Hospitalar de Lisboa Ocidental-Hospital Egas Moniz, CEDOC/NOVA Medical School, Nova University of Lisbon, Lisbon, Portugal
| | - René Rizzoli
- Department of Osteoporosis, Inselspital-Bern University Hospital, University of Bern, Bern, Switzerland
| | - Cyrus Cooper
- MRC Lifecourse Epidemiology Centre, University of Southampton, Tremona Road, Southampton, SO16 6YD, UK.
- Department of Rheumatology, Univ. Lille, CHU Lille, MABlab ULR 4490, 59000, Lille, France.
- NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK.
| |
Collapse
|
8
|
Kurth A, Weber U, Reichenbacher D. Maintaining differential pressure gradients does not increase safety inside modern BSL-4 laboratories. Front Bioeng Biotechnol 2022; 10:953675. [PMID: 36110311 PMCID: PMC9468669 DOI: 10.3389/fbioe.2022.953675] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Accepted: 07/18/2022] [Indexed: 11/13/2022] Open
Abstract
This article discusses a previously unrecognized contradiction in the design of biosafety level-4 (BSL-4) suit laboratories, also known as maximum or high containment laboratories. For decades, it is suggested that both directional airflow and pressure differentials are essential safety measures to prevent the release of pathogens into the environment and to avoid cross-contamination between laboratory rooms. Despite the absence of an existing evidence-based risk analyses demonstrating increased safety by directional airflow and pressure differentials in BSL-4 laboratories, they were anchored in various national regulations. Currently, the construction and operation of BSL-4 laboratories are subject to rigorous quality and technical requirements including airtight containment. Over time, BSL-4 laboratories evolved to enormously complex technical infrastructures. With the aim to counterbalance this development towards technical simplification while still maintaining maximum safety, we provide a detailed risk analysis by calculating pathogen mitigation in maximum contamination scenarios. The results presented and discussed herein, indicate that both directional airflow or a differential pressure gradient in airtight rooms within a secondary BSL-4 containment do not increase biosafety, and are not necessary. Likewise, reduction of pressure zones from the outside into the secondary containment may also provide sufficient environmental protection. We encourage laboratory design professionals to consider technical simplification and policymakers to adapt corresponding legislation and regulations surrounding directional airflow and pressure differentials for technically airtight BSL-4 laboratories.
Collapse
Affiliation(s)
- Andreas Kurth
- Biosafety Level-4 Laboratory, Robert Koch Institute, Centre for Biological Threats and Special Pathogens, Berlin, Germany
- *Correspondence: Andreas Kurth,
| | - Udo Weber
- Ingenieurbüro Udo Weber, Köln, Germany
| | - Detlef Reichenbacher
- Construction, Physical Plant and Technology, Robert Koch Institute, Central Services, Berlin, Germany
| |
Collapse
|
9
|
Wozniak DM, Riesle-Sbarbaro SA, Kirchoff N, Hansen-Kant K, Wahlbrink A, Stern A, Lander A, Hartmann K, Krasemann S, Kurth A, Prescott J. Inoculation route-dependent Lassa virus dissemination and shedding dynamics in the natural reservoir - Mastomys natalensis. Emerg Microbes Infect 2021; 10:2313-2325. [PMID: 34792436 PMCID: PMC8654411 DOI: 10.1080/22221751.2021.2008773] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Lassa virus (LASV), a Risk Group-4 zoonotic haemorrhagic fever virus, affects sub-Saharan African countries. Lassa fever, caused by LASV, results in thousands of annual deaths. Although decades have elapsed since the identification of the Natal multimammate mouse (Mastomys natalensis) as a natural reservoir of LASV, little effort has been made to characterize LASV infection in its reservoir. The natural route of infection and transmission of LASV within M. natalensis remains unknown, and the clinical impact of LASV in M. natalensis is mostly undescribed. Herein, using an outbred colony of M. natalensis, we investigate the replication and dissemination dynamics of LASV in this reservoir following various inoculation routes. Inoculation with LASV, regardless of route, resulted in a systemic infection and accumulation of abundant LASV-RNA in many tissues. LASV infection in the Natal multimammate mice was subclinical, however, clinical chemistry values were transiently altered and immune infiltrates were observed histologically in lungs, spleens and livers, indicating a minor disease with coordinated immune responses are elicited, controlling infection. Intranasal infection resulted in unique virus tissue dissemination dynamics and heightened LASV shedding, compared to subcutaneous inoculation. Our study provides important insights into LASV infection in its natural reservoir using a contemporary infection system, demonstrating that specific inoculation routes result in disparate dissemination outcomes, suggesting intranasal inoculation is important in the maintenance of LASV in the natural reservoir, and emphasizes that selection of the appropriate inoculation route is necessary to examine aspects of viral replication, transmission and responses to zoonotic viruses in their natural reservoirs.
Collapse
Affiliation(s)
- D M Wozniak
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| | | | - N Kirchoff
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| | - K Hansen-Kant
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| | - A Wahlbrink
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| | - A Stern
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| | - A Lander
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| | - K Hartmann
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - S Krasemann
- Institute of Neuropathology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - A Kurth
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| | - J Prescott
- ZBS5-Biosafety Level-4 Laboratory, Robert Koch-Institute, Berlin, Germany
| |
Collapse
|
10
|
Bokelmann M, Vogel U, Debeljak F, Düx A, Riesle-Sbarbaro S, Lander A, Wahlbrink A, Kromarek N, Neil S, Couacy-Hymann E, Prescott J, Kurth A. Tolerance and Persistence of Ebola Virus in Primary Cells from Mops condylurus, a Potential Ebola Virus Reservoir. Viruses 2021; 13:v13112186. [PMID: 34834992 PMCID: PMC8622823 DOI: 10.3390/v13112186] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/14/2021] [Accepted: 10/26/2021] [Indexed: 11/16/2022] Open
Abstract
Although there have been documented Ebola virus disease outbreaks for more than 40 years, the natural reservoir host has not been identified. Recent studies provide evidence that the Angolan free-tailed bat (Mops condylurus), an insectivorous microbat, is a possible ebolavirus reservoir. To investigate the potential role of this bat species in the ecology of ebolaviruses, replication, tolerance, and persistence of Ebola virus (EBOV) were investigated in 10 different primary bat cell isolates from M. condylurus. Varying EBOV replication kinetics corresponded to the expression levels of the integral membrane protein NPC1. All primary cells were highly tolerant to EBOV infection without cytopathic effects. The observed persistent EBOV infection for 150 days in lung primary cells, without resultant selective pressure leading to virus mutation, indicate the intrinsic ability of EBOV to persist in this bat species. These results provide further evidence for this bat species to be a likely reservoir of ebolaviruses.
Collapse
Affiliation(s)
- Marcel Bokelmann
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Uwe Vogel
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Franka Debeljak
- Department of Infectious Diseases, King’s College London, London WC2R 2LS, UK; (F.D.); (S.N.)
| | - Ariane Düx
- Epidemiology of Highly Pathogenic Microorganisms, Robert Koch Institute, 13353 Berlin, Germany;
| | - Silke Riesle-Sbarbaro
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Angelika Lander
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Annette Wahlbrink
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Nicole Kromarek
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Stuart Neil
- Department of Infectious Diseases, King’s College London, London WC2R 2LS, UK; (F.D.); (S.N.)
| | - Emmanuel Couacy-Hymann
- Laboratoire National d’Appui au Développement Agricole, Bingerville BP 206, Côte d’Ivoire;
| | - Joseph Prescott
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
| | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, 13353 Berlin, Germany; (M.B.); (U.V.); (S.R.-S.); (A.L.); (A.W.); (N.K.); (J.P.)
- Correspondence:
| |
Collapse
|
11
|
Chevalley T, Brandi ML, Cavalier E, Harvey NC, Iolascon G, Cooper C, Hannouche D, Kaux JF, Kurth A, Maggi S, Maier G, Papavasiliou K, Al-Daghri N, Sosa-Henríquez M, Suhm N, Tarantino U, Reginster JY, Rizzoli R. How can the orthopedic surgeon ensure optimal vitamin D status in patients operated for an osteoporotic fracture? Osteoporos Int 2021; 32:1921-1935. [PMID: 34013461 PMCID: PMC8134831 DOI: 10.1007/s00198-021-05957-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Accepted: 04/09/2021] [Indexed: 12/19/2022]
Abstract
In this narrative review, the role of vitamin D deficiency in the pathophysiology, healing of fragility fractures, and rehabilitation is discussed. Vitamin D status can be assessed by measuring serum 25(OH)-vitamin D level with standardized assays. There is a high prevalence of vitamin D insufficiency (25(OH)D < 50 nmol/l (i.e., 20 ng/mL)) or deficiency (25(OH)D < 25 nmol/l (i.e., 10 ng/mL)) in patients with fragility fractures and especially in those with a hip fracture. The evidence on the effects of vitamin D deficiency and/or vitamin D supplementation on fracture healing and material osseointegration is still limited. However, it appears that vitamin D have a rather positive influence on these processes. The fracture liaison service (FLS) model can help to inform orthopedic surgeons, all caregivers, and fractured patients about the importance of optimal vitamin D status in the management of patients with fragility fractures. Therefore, vitamin D status should be included in Capture the Fracture® program as an outcome of FLS in addition to dual-energy X-ray absorptiometry (DXA) and specific antiosteoporosis medication. Vitamin D plays a significant role in the pathophysiology and healing of fragility fractures and in rehabilitation after fracture. Correction of vitamin D deficiency should be one of the main outcomes in fracture liaison services.
Collapse
Affiliation(s)
- T Chevalley
- Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
| | - M L Brandi
- Metabolic Bone Diseases Unit, Department of Surgery and Translational Medicine, University of Florence, Florence, Italy
| | - E Cavalier
- Department of Clinical Chemistry, University of Liege, CHU de Liege, Liege, Belgium
| | - N C Harvey
- MRC Lifecourse Epidemiology Unit, NIHR Southampton Biomedical Research Centre, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - G Iolascon
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - C Cooper
- MRC Lifecourse Epidemiology Unit, NIHR Southampton Biomedical Research Centre, University of Southampton, University Hospital Southampton NHS Foundation Trust, Southampton, UK
- UKNIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK
| | - D Hannouche
- Service of Orthopaedics and Trauma Surgery, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - J-F Kaux
- Department of Physical Medicine and Rehabilitation, University and University Hospital of Liège, Liège, Belgium
| | - A Kurth
- Department of Orthopaedic and Trauma Surgery, Campus Kemperhof, Community Clinics Middle Rhine, Koblenz, Germany
| | - S Maggi
- CNR Aging Branch-IN, Padua, Italy
| | - G Maier
- Department of Orthopaedic and Rheumatological Rehabilitation, Rehazentrum am Meer, Bad Zwischenahn, Germany
| | - K Papavasiliou
- 3rd Orthopaedic Department, Aristotle University of Thessaloniki Medical School, Papageorgiou General Hospital, Thessaloniki, Greece
| | - N Al-Daghri
- Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science King Saud University, Riyadh, 11451, Saudi Arabia
| | - M Sosa-Henríquez
- University Institute of Investigation on Biomedical Sciences (IUIBMS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Canary Islands, Spain
- Bone Metabolic Unit, Hospital University Insular, Las Palmas de Gran Canaria, Canary Islands, Spain
| | - N Suhm
- Department of Orthopaedic and Trauma Surgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland
| | - U Tarantino
- Department of Clinical Sciences and Translational Medicine, Faculty of Medicine and Surgery, Tor Vergata University of Rome, Via Montpellier 1, 00133, Rome, Italy
| | - J-Y Reginster
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - R Rizzoli
- Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| |
Collapse
|
12
|
Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, Oudard S, Bruland Ø, Flamen P, Kurth A, Van Poznak C, Aapro M, Jordan K. Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 2020; 31:1650-1663. [PMID: 32801018 DOI: 10.1016/j.annonc.2020.07.019] [Citation(s) in RCA: 200] [Impact Index Per Article: 50.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Accepted: 07/26/2020] [Indexed: 12/16/2022] Open
Affiliation(s)
- R Coleman
- Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK
| | - P Hadji
- Frankfurt Centre of Bone Health, Frankfurt, Germany; Philipps University of Marburg, Marburg, Germany
| | - J-J Body
- CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium
| | - D Santini
- Medical Oncology Department, University Campus Bio-Medico, Rome, Italy
| | - E Chow
- Department of Radiation Oncology, University of Toronto, Toronto, Canada
| | - E Terpos
- National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
| | - S Oudard
- Department of Medical Oncology, Georges Pompidou Hospital, Paris Descartes University, Paris, France
| | - Ø Bruland
- Institute of Clinical Medicine, University of Oslo, Oslo, Norway; Department of Oncology, Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway
| | - P Flamen
- Department of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
| | - A Kurth
- Department of Orthopaedic and Trauma Surgery, Campus Kemperhof, Community Clinics Middle Rhine, Koblenz, Germany; Major Teaching Hospital of the University Medicine Mainz, Mainz, Germany
| | | | - M Aapro
- Genolier Cancer Centre, Genolier, Switzerland
| | - K Jordan
- Department of Medicine V, Hematology, Oncology and Rheumatology, University of Heidelberg, Heidelberg, Germany
| |
Collapse
|
13
|
Surtees R, Stern D, Ahrens K, Kromarek N, Lander A, Kreher P, Weiss S, Hewson R, Punch EK, Barr JN, Witkowski PT, Couacy-Hymann E, Marzi A, Dorner BG, Kurth A. Development of a multiplex microsphere immunoassay for the detection of antibodies against highly pathogenic viruses in human and animal serum samples. PLoS Negl Trop Dis 2020; 14:e0008699. [PMID: 33095766 PMCID: PMC7641473 DOI: 10.1371/journal.pntd.0008699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2020] [Revised: 11/04/2020] [Accepted: 08/11/2020] [Indexed: 11/18/2022] Open
Abstract
Surveillance of highly pathogenic viruses circulating in both human and animal populations is crucial to unveil endemic infections and potential zoonotic reservoirs. Monitoring the burden of disease by serological assay could be used as an early warning system for imminent outbreaks as an increased seroprevalance often precedes larger outbreaks. However, the multitude of highly pathogenic viruses necessitates the need to identify specific antibodies against several targets from both humans as well as from potential reservoir animals such as bats. In order to address this, we have developed a broadly reactive multiplex microsphere immunoassay (MMIA) for the detection of antibodies against several highly pathogenic viruses from both humans and animals. To this aim, nucleoproteins (NP) of Ebola virus (EBOV), Marburg virus (MARV) and nucleocapsid proteins (NP) of Crimean-Congo haemorrhagic fever virus, Rift Valley fever virus and Dobrava-Belgrade hantavirus were employed in a 5-plex assay for IgG detection. After optimisation, specific binding to each respective NP was shown by testing sera from humans and non-human primates with known infection status. The usefulness of our assay for serosurveillance was shown by determining the immune response against the NP antigens in a panel of 129 human serum samples collected in Guinea between 2011 and 2012 in comparison to a panel of 88 sera from the German blood bank. We found good agreement between our MMIA and commercial or in-house reference methods by ELISA or IIFT with statistically significant higher binding to both EBOV NP and MARV NP coupled microspheres in the Guinea panel. Finally, the MMIA was successfully adapted to detect antibodies from bats that had been inoculated with EBOV- and MARV- virus-like particles, highlighting the versatility of this technique and potentially enabling the monitoring of wildlife as well as human populations with this assay. We were thus able to develop and validate a sensitive and broadly reactive high-throughput serological assay which could be used as a screening tool to detect antibodies against several highly pathogenic viruses.
Collapse
Affiliation(s)
- Rebecca Surtees
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Daniel Stern
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Katharina Ahrens
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Nicole Kromarek
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Angelika Lander
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Petra Kreher
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Sabrina Weiss
- Institute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany
| | - Roger Hewson
- Virology and Pathogenesis Group, National Infection Service, Public Health England, Porton Down, United Kingdom
| | - Emma K Punch
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom
| | - John N Barr
- School of Molecular and Cellular Biology, Faculty of Biological Sciences, University of Leeds, United Kingdom
| | - Peter T Witkowski
- Institute of Virology, Charité -Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany
| | | | - Andrea Marzi
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, United States of America
| | - Brigitte G Dorner
- Biological Toxins, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Andreas Kurth
- Biosafety Level-4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| |
Collapse
|
14
|
Bokelmann M, Edenborough K, Hetzelt N, Kreher P, Lander A, Nitsche A, Vogel U, Feldmann H, Couacy-Hymann E, Kurth A. Utility of primary cells to examine NPC1 receptor expression in Mops condylurus, a potential Ebola virus reservoir. PLoS Negl Trop Dis 2020; 14:e0007952. [PMID: 31961874 PMCID: PMC6994141 DOI: 10.1371/journal.pntd.0007952] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 01/31/2020] [Accepted: 11/20/2019] [Indexed: 12/17/2022] Open
Abstract
The significance of the integral membrane protein Niemann-Pick C1 (NPC1) in the ebolavirus entry process has been determined using various cell lines derived from humans, non-human primates and fruit bats. Fruit bats have long been purported as the potential reservoir host for ebolaviruses, however several studies provide evidence that Mops condylurus, an insectivorous microbat, is also an ebolavirus reservoir. NPC1 receptor expression in the context of ebolavirus replication in microbat cells remains unstudied. In order to study Ebola virus (EBOV) cellular entry and replication in M. condylurus, we derived primary and immortalized cell cultures from 12 different organs. The NPC1 receptor expression was characterized by confocal microscopy and flow cytometry comparing the expression levels of M. condylurus primary and immortalized cells, HeLa cells, human embryonic kidney cells and cells from a European microbat species. EBOV replication kinetics was studied for four representative cell cultures using qRT-PCR. The aim was to elucidate the suitability of primary and immortalized cells from different tissues for studying NPC1 receptor expression levels and their potential influence on EBOV replication. The NPC1 receptor expression level in M. condylurus primary cells differed depending on the organ they were derived from and was for most cell types significantly lower than in human cell lines. Immortalized cells showed for most cell types higher expression levels than their corresponding primary cells. Concluding from our infection experiments with EBOV we suggest a potential correlation between NPC1 receptor expression level and virus replication rate in vitro. Although there have been Ebola virus (EBOV) outbreaks for more than 40 years, the animal natural reservoir that maintains this virus in nature has not been identified. Viruses and their respective reservoirs coevolve over millions of years, often without causing diseases in the reservoir itself. Upon entering a new host, infection can have devastating consequences, as in the case of EBOV. To gain entry into cells prior to replication, all ebolaviruses utilize the cellular receptor Niemann-Pick C1 (NPC1). In this study the authors focus their work on the Angolan free-tailed bat (Mops condylurus) as a potential reservoir for EBOV. Cells from various organs of this bat were isolated in culture and tested for the presence of NPC1. Most bat cell types had a lower amount of NPC1 compared to the tested human cells. These bat cells were also less efficiently infected by EBOV, indicating adaptation to EBOV. These results suggest low levels of virus replication in the respective tissues of M. condylurus and might be indicative of a virus-natural reservoir relationship.
Collapse
Affiliation(s)
- Marcel Bokelmann
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Kathryn Edenborough
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Nicole Hetzelt
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Petra Kreher
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Angelika Lander
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Andreas Nitsche
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Uwe Vogel
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Heinz Feldmann
- Laboratory of Virology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT, United States of America
| | | | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- * E-mail:
| |
Collapse
|
15
|
Edenborough KM, Bokelmann M, Lander A, Couacy-Hymann E, Lechner J, Drechsel O, Renard BY, Radonić A, Feldmann H, Kurth A, Prescott J. Dendritic Cells Generated From Mops condylurus, a Likely Filovirus Reservoir Host, Are Susceptible to and Activated by Zaire Ebolavirus Infection. Front Immunol 2019; 10:2414. [PMID: 31681302 PMCID: PMC6797855 DOI: 10.3389/fimmu.2019.02414] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 09/26/2019] [Indexed: 12/17/2022] Open
Abstract
Ebola virus infection of human dendritic cells (DCs) induces atypical adaptive immune responses and thereby exacerbates Ebola virus disease (EVD). Human DCs, infected with Ebola virus aberrantly express low levels of the DC activation markers CD80, CD86, and MHC class II. The T cell responses ensuing are commonly anergic rather than protective against EVD. We hypothesize that DCs derived from potential reservoir hosts such as bats, which do not develop disease signs in response to Ebola virus infection, would exhibit features associated with activation. In this study, we have examined Zaire ebolavirus (EBOV) infection of DCs derived from the Angolan free-tailed bat species, Mops condylurus. This species was previously identified as permissive to EBOV infection in vivo, in the absence of disease signs. M. condylurus has also been recently implicated as the reservoir host for Bombali ebolavirus, a virus species that is closely related to EBOV. Due to the absence of pre-existing M. condylurus species-specific reagents, we characterized its de novo assembled transcriptome and defined its phylogenetic similarity to other mammals, which enabled the identification of cross-reactive reagents for M. condylurus bone marrow-derived DC (bat-BMDC) differentiation and immune cell phenotyping. Our results reveal that bat-BMDCs are susceptible to EBOV infection as determined by detection of EBOV specific viral RNA (vRNA). vRNA increased significantly 72 h after EBOV-infection and was detected in both cells and in culture supernatants. Bat-BMDC infection was further confirmed by the observation of GFP expression in DC cultures infected with a recombinant GFP-EBOV. Bat-BMDCs upregulated CD80 and chemokine ligand 3 (CCL3) transcripts in response to EBOV infection, which positively correlated with the expression levels of EBOV vRNA. In contrast to the aberrant responses to EBOV infection that are typical for human-DC, our findings from bat-BMDCs provide evidence for an immunological basis of asymptomatic EBOV infection outcomes.
Collapse
Affiliation(s)
- Kathryn M Edenborough
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Marcel Bokelmann
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Angelika Lander
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Emmanuel Couacy-Hymann
- LANADA, Laboratoire National d'Appui au Développement Agricole, Bingerville, Côte d'Ivoire
| | - Johanna Lechner
- Methodology and Research Infrastructure, Robert Koch Institute, Berlin, Germany
| | - Oliver Drechsel
- Methodology and Research Infrastructure, Robert Koch Institute, Berlin, Germany
| | - Bernhard Y Renard
- Methodology and Research Infrastructure, Robert Koch Institute, Berlin, Germany
| | - Aleksandar Radonić
- Methodology and Research Infrastructure, Robert Koch Institute, Berlin, Germany
| | - Heinz Feldmann
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, ON, United States
| | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Joseph Prescott
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| |
Collapse
|
16
|
Diez-Perez A, Brandi ML, Al-Daghri N, Branco JC, Bruyère O, Cavalli L, Cooper C, Cortet B, Dawson-Hughes B, Dimai HP, Gonnelli S, Hadji P, Halbout P, Kaufman JM, Kurth A, Locquet M, Maggi S, Matijevic R, Reginster JY, Rizzoli R, Thierry T. Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res 2019; 31:1375-1389. [PMID: 31422565 PMCID: PMC6763416 DOI: 10.1007/s40520-019-01294-4] [Citation(s) in RCA: 46] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2019] [Accepted: 07/24/2019] [Indexed: 01/19/2023]
Abstract
PURPOSE The purpose of this paper was to review the available approaches for bone strength assessment, osteoporosis diagnosis and fracture risk prediction, and to provide insights into radiofrequency echographic multi spectrometry (REMS), a non-ionizing axial skeleton technique. METHODS A working group convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis met to review the current image-based methods for bone strength assessment and fracture risk estimation, and to discuss the clinical perspectives of REMS. RESULTS Areal bone mineral density (BMD) measured by dual-energy X-ray absorptiometry (DXA) is the consolidated indicator for osteoporosis diagnosis and fracture risk assessment. A more reliable fracture risk estimation would actually require an improved assessment of bone strength, integrating also bone quality information. Several different approaches have been proposed, including additional DXA-based parameters, quantitative computed tomography, and quantitative ultrasound. Although each of them showed a somewhat improved clinical performance, none satisfied all the requirements for a widespread routine employment, which was typically hindered by unclear clinical usefulness, radiation doses, limited accessibility, or inapplicability to spine and hip, therefore leaving several clinical needs still unmet. REMS is a clinically available technology for osteoporosis diagnosis and fracture risk assessment through the estimation of BMD on the axial skeleton reference sites. Its automatic processing of unfiltered ultrasound signals provides accurate BMD values in view of fracture risk assessment. CONCLUSIONS New approaches for improved bone strength and fracture risk estimations are needed for a better management of osteoporotic patients. In this context, REMS represents a valuable approach for osteoporosis diagnosis and fracture risk prediction.
Collapse
Affiliation(s)
- Adolfo Diez-Perez
- Department of Internal Medicine, Hospital del Mar/IMIM and CIBERFES, Autonomous University of Barcelona, Passeig Maritim 25-29, 08003, Barcelona, Spain.
| | - Maria Luisa Brandi
- FirmoLab Fondazione F.I.R.M.O., Florence, Italy
- Department of Biological, Experimental and Clinical Science, University of Florence, Florence, Italy
| | - Nasser Al-Daghri
- Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Jaime C Branco
- NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal
| | - Olivier Bruyère
- WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, University of Liège, Liège, Belgium
| | - Loredana Cavalli
- FirmoLab Fondazione F.I.R.M.O., Florence, Italy
- Department of Biological, Experimental and Clinical Science, University of Florence, Florence, Italy
| | - Cyrus Cooper
- MRC Lifecourse Epidemiology Unit, Southampton General Hospital, University of Southampton, Southampton, UK
| | - Bernard Cortet
- Department of Rheumatology and EA 4490, University-Hospital of Lille, Lille, France
| | - Bess Dawson-Hughes
- Bone Metabolism Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging, Tufts University, Boston, MA, USA
| | - Hans Peter Dimai
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
| | - Stefano Gonnelli
- Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy
| | - Peyman Hadji
- Frankfurter Hormon und Osteoporose Zentrum, Frankfurt, Germany
| | | | - Jean-Marc Kaufman
- Department of Endocrinology, Ghent University Hospital, Ghent, Belgium
| | - Andreas Kurth
- Department of Orthopaedic Surgery and Osteology, Klinikum Frankfurt, Frankfurt, Germany
- Mayor Teaching Hospital, Charite Medical School, Berlin, Germany
| | - Medea Locquet
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - Stefania Maggi
- National Research Council, Aging Program, Institute of Neuroscience, Padua, Italy
| | - Radmila Matijevic
- Faculty of Medicine, University of Novi Sad, Novi Sad, Serbia
- Clinical Center of Vojvodina, Clinic for Orthopedic Surgery, Novi Sad, Serbia
| | - Jean-Yves Reginster
- Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science, King Saud University, Riyadh, Kingdom of Saudi Arabia
- WHO Collaborating Centre for Public Health Aspects of Musculoskeletal Health and Aging, University of Liège, Liège, Belgium
| | - René Rizzoli
- Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - Thomas Thierry
- Department of Rheumatology, Hospital Nord, CHU St Etienne, St Etienne, France
- INSERM 1059, University of Lyon, St Etienne, France
| |
Collapse
|
17
|
Hunger I, Becker S, Frank C, Grunow R, Herzog C, Kurth A, Monazahian M, Nitsche A, Sasse J, Schulz-Weidhaas C, Wollin KM, Schaade L. [Four years after the Ebola crisis : Challenges, experiences, and implications in the German public health context]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2019; 62:1041-1051. [PMID: 31428830 DOI: 10.1007/s00103-019-02995-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The Ebola virus disease outbreak in West Africa in 2014/2015 was by far the biggest, most prolonged, and geographically most widespread outbreak of this disease since the discovery of the Ebola virus in 1976. Although no cases of Ebola virus disease were confirmed in Germany, a number of crisis management activities were initiated.Based on a combination of local, national, and international lessons learned, literature research, and a large number of discussions among German colleagues as well as German and foreign colleagues, the experiences of selected German public health actors as well as implications for health protection activities in Germany are presented.On the one hand, preparedness for managing unusual high consequence health events-caused by rare, highly pathogenic biological agents-including the provision of adequate material and personnel resources remains important in Germany. On the other hand, more German engagement in global health is necessary, because the dividing line between global health and local health is increasingly disappearing.
Collapse
Affiliation(s)
- Iris Hunger
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland.
| | - Stephan Becker
- Institut für Virologie, Philipps-Universität Marburg, Marburg, Deutschland
| | - Christina Frank
- Abteilung für Infektionsepidemiologie, Robert Koch-Institut, Berlin, Deutschland
| | - Roland Grunow
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland
| | - Christian Herzog
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland
| | - Andreas Kurth
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland
| | - Masyar Monazahian
- Zentrum für Gesundheits- und Infektionsschutz, Niedersächsisches Landesgesundheitsamt, Hannover, Deutschland
| | - Andreas Nitsche
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland
| | - Julia Sasse
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland
| | - Claudia Schulz-Weidhaas
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland
| | - Klaus-Michael Wollin
- Zentrum für Gesundheits- und Infektionsschutz, Niedersächsisches Landesgesundheitsamt, Hannover, Deutschland
| | - Lars Schaade
- Zentrum für Biologische Gefahren und Spezielle Pathogene, Robert Koch-Institut, Seestraße 10, 13353, Berlin, Deutschland
| |
Collapse
|
18
|
Chavez F, Kelly T, Kunisch JR, Kurth A. Systems leadership doctor of nursing practice: global relevance. Int Nurs Rev 2019; 66:482-489. [PMID: 31206651 DOI: 10.1111/inr.12527] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
AIM This article considers the systems leadership doctor of nursing practice degree as an option to increase nursing leadership roles and heighten presence at policy tables globally, particularly in low- and middle-income countries. Recent global reports emphasize core competencies needed for nursing leadership, particularly systems leadership and health policy, to successfully move the global health agenda forward. Using the Yale University School of Nursing programme as an exemplar, this paper is focused on the elements directly linked to leadership competencies and relevance of a systems leadership doctor of nursing practice programme globally. BACKGROUND/INTRODUCTION The dramatic growth and wide variability of doctor of nursing practice programmes offered in all 50 US States have generated questions and debate. According to the American Association of Colleges of Nursing as of May 2018, there are 121 schools that reported having a leadership focus in postmaster's doctor of nursing practice degree offering. Yet there has not been the same enthusiasm for development and implementation for a practice doctorate in nursing across the globe. SOURCES OF EVIDENCE A narrative literature review was conducted aimed at addressing the relevance of a practice doctorate globally. This analysis of the literature included a search of peer-reviewed and grey literature. Nursing school websites were visited, and opinions of nurse leaders and students were sought. In addition, global reports that supported nursing leadership and their role in policy development were reviewed. DISCUSSION/CONCLUSION Globally, nurses have a critical role in leading health systems. Developing a cadre of nurse leaders educated at the doctoral level who can communicate with policymakers and develop strategies to meet health systems' goals is necessary. IMPLICATIONS FOR NURSING, HEALTH AND EDUCATION POLICY In recent global health reports and campaigns, strengthening nursing leadership and presence at policymaking tables are recurring themes. Offering a systems leadership doctor of nursing practice degree is one viable option to increase doctorally prepared nurse leaders for nursing policy and practice engagement. This calls for work with country and regional governments, regulatory bodies and nursing associations to empower nursing to contribute fully.
Collapse
Affiliation(s)
- F Chavez
- Teaching Stream, Bloomberg Faculty of Nursing, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
| | | | | | | |
Collapse
|
19
|
Dimai HP, Ljuhar R, Ljuhar D, Norman B, Nehrer S, Kurth A, Fahrleitner-Pammer A. Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial. Skeletal Radiol 2019; 48:1023-1032. [PMID: 30506302 PMCID: PMC6525665 DOI: 10.1007/s00256-018-3118-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/21/2018] [Revised: 10/15/2018] [Accepted: 11/14/2018] [Indexed: 02/02/2023]
Abstract
OBJECTIVE To evaluate the clinical applicability of a software tool developed to extract bone textural information from conventional lumbar spine radiographs, and to test it in a subset of postmenopausal women treated for osteoporosis with the fully human monoclonal antibody denosumab. METHODS The software was developed based on the principles of a fractal model using pixel grey-level variations together with a specific machine-learning algorithm. The obtained dimensionless parameter, termed bone structure value (BSV), was then tested and compared to bone mineral density (BMD) in a sub-cohort of postmenopausal women with osteoporosis who were treated with the monoclonal antibody denosumab, within the framework of a large randomized controlled trial and its open-label extension phase. RESULTS After 3 years and after 8 years of treatment with denosumab, mean lumbar spine BMD as well as mean lumbar BSV were significantly higher compared to study entry (one-way repeated measures ANOVA for DXA: F = 108.2, p < 0.00001; and for BSV: F = 84.3, p < 0.00001). The overall increase in DXA-derived lumbar spine BMD at year 8 was + 42% (mean ± SD; 0.725 ± 0.038 g/cm2 to 1.031 ± 0.092 g/cm2; p < 0.0001), and the overall increase of BSV was 255% (mean ± SD; 0.076 ± 0.022 to 0.270 ± 0.09, p < 0.0001). Overall, BMD and BSV were significantly correlated (R = 0.51; p < 0.0001). CONCLUSIONS This pilot study provides evidence that lumbar spine BSV as obtained from conventional radiographs constitutes a useful means for the assessment of bone-specific treatment effects in postmenopausal women with osteoporosis.
Collapse
Affiliation(s)
- Hans Peter Dimai
- Department of Internal Medicine, Division of Endocrinology & Diabetology, Medical University of Graz, Auenbruggerpl. 15, 8036, Graz, Austria.
| | - Richard Ljuhar
- Image Biopsy Lab, Research & Development, Vienna, Austria
| | | | | | - Stefan Nehrer
- Department for Health Sciences and Biomedicine, Center for Regenerative Medicine and Orthopedics, Danube University Krems, Krems, Austria
| | | | - Astrid Fahrleitner-Pammer
- Department of Internal Medicine, Division of Endocrinology & Diabetology, Medical University of Graz, Auenbruggerpl. 15, 8036, Graz, Austria
| |
Collapse
|
20
|
Kohl C, Tachedjian M, Todd S, Monaghan P, Boyd V, Marsh GA, Crameri G, Field H, Kurth A, Smith I, Wang LF. Hervey virus: Study on co-circulation with Henipaviruses in Pteropid bats within their distribution range from Australia to Africa. PLoS One 2018; 13:e0191933. [PMID: 29390028 PMCID: PMC5794109 DOI: 10.1371/journal.pone.0191933] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 01/15/2018] [Indexed: 11/25/2022] Open
Abstract
In 2011, an unusually large number of independent Hendra virus outbreaks were recorded on horse properties in Queensland and New South Wales, Australia. Urine from bat colonies adjacent to the outbreak sites were sampled and screened for Hendra and other viruses. Several novel paramyxoviruses were also isolated at different locations. Here one of the novel viruses, named Hervey virus (HerPV), is fully characterized by genome sequencing, annotation, phylogeny and in vitro host range, and its serological cross-reactivity and neutralization patterns are examined. HerPV may have ecological and spatial and temporal patterns similar to Hendra virus and could serve as a sentinel virus for the surveillance of this highly pathogenic virus. The suitability of HerPV as potential sentinel virus is further assessed by determining the serological prevalence of HerPV antibodies in fruit-eating bats from Australia, Indonesia, Papua New Guinea, Tanzania and the Gulf of Guinea, indicating the presence of similar viruses in regions beyond the Australian border.
Collapse
Affiliation(s)
- Claudia Kohl
- Robert Koch Institute, Centre for Biological Threats and Special Pathogens, Seestraße 10, Berlin, Germany
| | - Mary Tachedjian
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
| | - Shawn Todd
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
| | - Paul Monaghan
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
| | - Victoria Boyd
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
| | - Glenn A. Marsh
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
| | - Gary Crameri
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
| | - Hume Field
- Queensland Centre for Emerging Infectious Diseases, Department of Agriculture and Fisheries, Brisbane, Queensland, Australia
- EcoHealth Alliance, New York, United States of America
| | - Andreas Kurth
- Robert Koch Institute, Centre for Biological Threats and Special Pathogens, Seestraße 10, Berlin, Germany
| | - Ina Smith
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
- * E-mail: (IS); (LFW)
| | - Lin-Fa Wang
- CSIRO Health and Biosecurity, Australian Animal Health Laboratory, Geelong, Victoria, Australia
- Programme in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore, Singapore
- * E-mail: (IS); (LFW)
| |
Collapse
|
21
|
Kohl C, Kurth A. Tissue-Based Universal Virus Detection (TUViD-VM) Protocol for Viral Metagenomics. Methods Mol Biol 2018; 1838:15-23. [PMID: 30128986 DOI: 10.1007/978-1-4939-8682-8_2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
The protocol for tissue-based universal virus detection (TUViD-VM) was developed to allow for the detection of yet unknown viruses from infected tissues. Tissues are a challenging source when it comes to virus detection. The very rapid degradation rate of tissue and the high level of host nucleic acids are the biggest challenges when examining tissues. However, to overcome these challenges, we had to decrease the amount of host nucleic acids rigorously in order to increase the amount of viral nucleic acids. We compared modern and common virological approaches to find the optimal conditions. The final TUViD-VM protocol was extensively validated by using real-time PCR and next-generation sequencing. We could increase the amount of detectable virus nucleic acids and improved the detection of viruses <75,000-fold compared with other approaches tested. The TUViD-VM protocol can be used in metagenomic and virome studies to increase the likelihood of detecting viruses from any biological source. The protocol has been widely used to detect viruses in different tissues with great success. Here we provide the bench-top protocol version of the TUViD-VM protocol.
Collapse
Affiliation(s)
- Claudia Kohl
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany.
| | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| |
Collapse
|
22
|
Amling M, Baier M, Blattert T, Euler E, Götte S, Kaps P, Kasperk H, Kurth A, Meeder PJ, Schwarz H, Steinleitner WE, Weißkopf M, Haas H. Zur Anwendung der Ballon-Kyphoplastie/Vertebroplastie. ACTA ACUST UNITED AC 2017. [DOI: 10.1055/s-0037-1619843] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
ZusammenfassungIn der Behandlung osteoporotischer Wirbelkörperfrakturen finden die minimalinvasiven Methoden der Ballon-Kyphoplastie und der Vertebroplastie zunehmende Verbreitung. In der aktuellen Leitlinie zur Behandlung der Osteoporose ist aufgrund der eingeschränkten Studienlage eine sehr konservative Aussage zur Anwendung der Verfahren getroffen worden. Die vorliegende Arbeit stellt eine Bewertung beider Verfahren hinsichtlich Indikation, technischer Durchführung und notwendiger Voraussetzungen dar. Sie wurde erstellt durch eine vom DVO beauftragte Arbeitsgruppe und soll bestehende Unsicherheiten im Zusammenhang mit beiden Verfahren reduzieren.
Collapse
|
23
|
Rizzo F, Edenborough KM, Toffoli R, Culasso P, Zoppi S, Dondo A, Robetto S, Rosati S, Lander A, Kurth A, Orusa R, Bertolotti L, Mandola ML. Coronavirus and paramyxovirus in bats from Northwest Italy. BMC Vet Res 2017; 13:396. [PMID: 29273042 PMCID: PMC5741894 DOI: 10.1186/s12917-017-1307-x] [Citation(s) in RCA: 31] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2017] [Accepted: 11/28/2017] [Indexed: 01/10/2023] Open
Abstract
Background Bat-borne virus surveillance is necessary for determining inter-species transmission risks and is important due to the wide-range of bat species which may harbour potential pathogens. This study aimed to monitor coronaviruses (CoVs) and paramyxoviruses (PMVs) in bats roosting in northwest Italian regions. Our investigation was focused on CoVs and PMVs due to their proven ability to switch host and their zoonotic potential. Here we provide the phylogenetic characterization of the highly conserved polymerase gene fragments. Results Family-wide PCR screenings were used to test 302 bats belonging to 19 different bat species. Thirty-eight animals from 12 locations were confirmed as PCR positive, with an overall detection rate of 12.6% [95% CI: 9.3–16.8]. CoV RNA was found in 36 bats belonging to eight species, while PMV RNA in three Pipistrellus spp. Phylogenetic characterization have been obtained for 15 alpha- CoVs, 5 beta-CoVs and three PMVs; moreover one P. pipistrellus resulted co-infected with both CoV and PMV. A divergent alpha-CoV clade from Myotis nattereri SpA is also described. The compact cluster of beta-CoVs from R. ferrumequinum roosts expands the current viral sequence database, specifically for this species in Europe. To our knowledge this is the first report of CoVs in Plecotus auritus and M. oxygnathus, and of PMVs in P. kuhlii. Conclusions This study identified alpha and beta-CoVs in new bat species and in previously unsurveyed Italian regions. To our knowledge this represents the first and unique report of PMVs in Italy. The 23 new bat genetic sequences presented will expand the current molecular bat-borne virus databases. Considering the amount of novel bat-borne PMVs associated with the emergence of zoonotic infections in animals and humans in the last years, the definition of viral diversity within European bat species is needed. Performing surveillance studies within a specific geographic area can provide awareness of viral burden where bats roost in close proximity to spillover hosts, and form the basis for the appropriate control measures against potential threats for public health and optimal management of bats and their habitats.
Collapse
Affiliation(s)
- Francesca Rizzo
- Istituto zooprofilattico sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10148, Torino, Italy.
| | | | - Roberto Toffoli
- Chirosphera, via Tetti Barbiere 11, 10026, Santena, TO, Italy
| | - Paola Culasso
- Chirosphera, via Tetti Barbiere 11, 10026, Santena, TO, Italy
| | - Simona Zoppi
- Istituto zooprofilattico sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10148, Torino, Italy
| | - Alessandro Dondo
- Istituto zooprofilattico sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10148, Torino, Italy
| | - Serena Robetto
- Istituto zooprofilattico sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10148, Torino, Italy
| | - Sergio Rosati
- Department of Veterinary Science, Largo Paolo Braccini 2, 10095, Grugliasco, TO, Italy
| | | | - Andreas Kurth
- Robert Koch Institute, Seestraße 10, 13353, Berlin, Germany
| | - Riccardo Orusa
- Istituto zooprofilattico sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10148, Torino, Italy
| | - Luigi Bertolotti
- Department of Veterinary Science, Largo Paolo Braccini 2, 10095, Grugliasco, TO, Italy
| | - Maria Lucia Mandola
- Istituto zooprofilattico sperimentale del Piemonte, Liguria e Valle d'Aosta, Via Bologna 148, 10148, Torino, Italy
| |
Collapse
|
24
|
Stagegaard J, Kurth A, Stern D, Dabrowski PW, Pocknell A, Nitsche A, Schrick L. Seasonal recurrence of cowpox virus outbreaks in captive cheetahs (Acinonyx jubatus). PLoS One 2017; 12:e0187089. [PMID: 29121668 PMCID: PMC5679633 DOI: 10.1371/journal.pone.0187089] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2017] [Accepted: 10/15/2017] [Indexed: 11/18/2022] Open
Abstract
Cowpox virus infections in captive cheetahs (Acinonyx jubatus) with high morbidity and mortality have already been reported in the UK and Russia in the 1970s. However, most of the reported cases have been singular events. Here, we report a total of five cowpox virus outbreaks in cheetahs in the same safari park in Denmark between 2010 and 2014. Nine cheetahs showed varying severity of clinical disease; two of them died (22%). All episodes occurred between August and October of the respective year. No other carnivores kept at the same institution nor the keepers taking care of the animals were clinically affected. The clinical picture of cowpox was confirmed by extensive laboratory investigations including histopathological and molecular analyses as well as cell culture isolation of a cowpox virus. High anti-orthopoxvirus antibody titers were detected in all 9 diseased cheetahs compared to seven contact cheetahs without clinical signs and 13 cheetahs not in direct contact. Additionally, whole genome sequencing from one sample of each cluster with subsequent phylogenetic analysis showed that the viruses from different outbreaks have individual sequences but clearly form a clade distinct from other cowpox viruses. However, the intra-clade distances are still larger than those usually observed within clades of one event. These findings indicate multiple and separate introductions of cowpox virus, probably from wild rodent populations, where the virus keeps circulating naturally and is only sporadically introduced into the cheetahs. Sero-positivity of voles (Arvicola amphibious) caught in zoo grounds strengthens this hypothesis. As a consequence, recommendations are given for medical and physical management of diseased cheetahs, for hygienic measures as well as for pre-shipment isolation before cheetah export from zoo grounds.
Collapse
Affiliation(s)
| | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- German Consultant Laboratory for Poxviruses, Robert Koch Institute, Berlin, Germany
| | - Daniel Stern
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | | | | | - Andreas Nitsche
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- German Consultant Laboratory for Poxviruses, Robert Koch Institute, Berlin, Germany
- * E-mail:
| | - Livia Schrick
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
- German Consultant Laboratory for Poxviruses, Robert Koch Institute, Berlin, Germany
| |
Collapse
|
25
|
Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, Cannata-Andia J, Cortet B, Dimai HP, Ferrari S, Hadji P, Harvey NC, Kraenzlin M, Kurth A, McCloskey E, Minisola S, Thomas T, Reginster JY. Erratum to: Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 2017; 28:3285-3286. [PMID: 28785979 PMCID: PMC6829798 DOI: 10.1007/s00198-017-4161-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- J A Kanis
- Centre forMetabolic Bone Diseases, University of SheffieldMedical School, Beech Hill Road, Sheffield, S10 2RX, UK.
- Institute for Health and Ageing, Catholic University of Australia, Melbourne, Australia.
| | - C Cooper
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
- NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
| | - R Rizzoli
- Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - B Abrahamsen
- Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - N M Al-Daghri
- Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia
| | - M L Brandi
- Department of Surgery and Translational Medicine, Unit of Bone and Mineral Diseases, University of Florence, Florence, Italy
| | - J Cannata-Andia
- Bone and Mineral Research Unit, Instituto "Reina Sofía" de Investigación, REDinREN ISCIII, Hospital Universitario Central de Asturias, Universidad de Oviedo, Asturias, Spain
| | - B Cortet
- Department of Rheumatology, Lille University Hospital, Lille, France
| | - H P Dimai
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
| | - S Ferrari
- Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - P Hadji
- Department of Bone Oncology, Endocrinology and Reproductive Medicine, Krankenhaus Nordwest, Frankfurt, Germany
| | - N C Harvey
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
| | - M Kraenzlin
- Endonet, Endocrine Clinic and Laboratory, Basel, Switzerland
| | - A Kurth
- Department of Orthopaedic Surgery and Osteology, Klinikum Frankfurt, Frankfurt, Germany
- Mayor Teaching Hospital, Charitè Medical School, Berlin, Germany
| | - E McCloskey
- Centre forMetabolic Bone Diseases, University of SheffieldMedical School, Beech Hill Road, Sheffield, S10 2RX, UK
- MRC and Arthritis Research UK Centre for Integrated Research in Musculoskeletal Ageing, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK
| | - S Minisola
- Department of Internal Medicine and Medical Disciplines, "Sapienza" Università di Roma, Rome, Italy
| | - T Thomas
- INSERM U1059, Laboratoire Biologie Intégrée du Tissu Osseux, Rheumatology Department, CHU Saint-Etienne, Université de Lyon, Saint-Etienne, France
| | - J-Y Reginster
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | | |
Collapse
|
26
|
Kohl C, Wegener M, Nitsche A, Kurth A. Use of RNALater® Preservation for Virome Sequencing in Outbreak Settings. Front Microbiol 2017; 8:1888. [PMID: 29018436 PMCID: PMC5623189 DOI: 10.3389/fmicb.2017.01888] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2017] [Accepted: 09/14/2017] [Indexed: 11/25/2022] Open
Abstract
Outbreaks of infectious diseases may occur in animal and human populations; this underlines the need for suitable One Health approaches. During outbreak situations, straightforward identification of etiological agents is indispensable for taking countermeasures. A recently published protocol for metagenomic virus detection in clinical specimens (TUViD-VM) was developed for snap-frozen tissues which can be challenging to obtain. Here, we describe the use of RNALater®-treated tissue at ambient temperatures for virome sequencing. This study demonstrates that samples stored in RNALater® buffer yield similar results to those stored snap-frozen.
Collapse
Affiliation(s)
- Claudia Kohl
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Merle Wegener
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Andreas Nitsche
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| |
Collapse
|
27
|
Weiss S, Dabrowski PW, Kurth A, Leendertz SAJ, Leendertz FH. A novel Coltivirus-related virus isolated from free-tailed bats from Côte d'Ivoire is able to infect human cells in vitro. Virol J 2017; 14:181. [PMID: 28923111 PMCID: PMC5604424 DOI: 10.1186/s12985-017-0843-0] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2017] [Accepted: 08/31/2017] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND Zoonotic transmission events play a major role in the emergence of novel diseases. While such events are virtually impossible to predict, wildlife screening for potential emerging pathogens can be a first step. Driven by recent disease epidemics like severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and Ebola, bats have gained special interest as reservoirs of emerging viruses. METHODS As part of a bigger study investigating pathogens in African bats we screened animals for the presence of known and unknown viruses. RESULTS We isolated and characterised a novel reovirus from blood of free-tailed bats (Chaereophon aloysiisabaudiae) captured in 2006 in Côte d'Ivoire. The virus showed closest relationship with two human pathogenic viruses, Colorado tick fever virus and Eyach virus, and was able to infect various human cell lines in vitro. CONCLUSION The study shows the presence of a coltivirus-related virus in bats from Sub-Sahara Africa. Serological studies could help to assess its impact on humans or wildlife health.
Collapse
Affiliation(s)
- Sabrina Weiss
- Robert Koch-Institut, Epidemiology of Highly Pathogenic Microorganisms (P3), Seestrasse 10, 13353, Berlin, Germany. .,Current Address: Charité - Universitätsmedizin Berlin, Institute of Virology, Charitéplatz 1, 10117, Berlin, Germany.
| | - Piotr Wojtek Dabrowski
- Robert Koch-Institut, Methodology and Research Infrastructure 1 - Bioinformatics, Seestraße 10, 13353, Berlin, Germany.,Robert Koch-Institut, Centre for Biological Threats and Special Pathogens 1 (ZBS1), Seestraße 10, 13353, Berlin, Germany
| | - Andreas Kurth
- Robert Koch-Institut, Biosafety Level 4-Laboratory (ZBS5), Seestrasse 10, 13353, Berlin, Germany
| | - Siv Aina J Leendertz
- Robert Koch-Institut, Epidemiology of Highly Pathogenic Microorganisms (P3), Seestrasse 10, 13353, Berlin, Germany
| | - Fabian H Leendertz
- Robert Koch-Institut, Epidemiology of Highly Pathogenic Microorganisms (P3), Seestrasse 10, 13353, Berlin, Germany
| |
Collapse
|
28
|
Horas K, Maier G, Jakob F, Maus U, Kurth A, Jakuscheit A, Rudert M, Holzapfel BM. High Prevalence of Vitamin D Deficiency in Patients with Bone Tumors. Cancer Invest 2017; 35:562-568. [PMID: 28799812 DOI: 10.1080/07357907.2017.1351985] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The aim of this study was to evaluate the prevalence of vitamin D deficiency in patients with different types of bone tumors and to elucidate whether or not there are differences in prediagnostic vitamin D levels in patients with malignant compared to benign bone tumors. Prediagnostic serum 25(OH)D levels of 105 consecutive patients that presented with bone tumors and tumor-like lesions to two Orthopedic Level I University Centers in Germany between 2011 and 2016 were measured on admission. We found an alarming and widespread rate of vitamin D deficiency in patients with bone tumors. Specifically, 83% of all patients had low vitamin D levels with a mean 25(OH)D level of 19.82 ng/ml. Notably, patients diagnosed with malignant bone tumors had significantly lower vitamin D levels compared to patients with benign bone lesions (p = 0.0008). In conclusion, it is essential to assess vitamin D levels in patients with tumors involving bone. In addition, there might be an association between vitamin D deficiency and the onset or course of primary malignant bone tumors.
Collapse
Affiliation(s)
- Konstantin Horas
- a Department of Orthopedics , Koenig-Ludwig-Haus, University of Wuerzburg , Wuerzburg , Germany.,c Orthopedic Center for Musculoskeletal Research, Orthopedic Department , University of Wuerzburg , Wuerzburg , Germany
| | - Gerrit Maier
- b Department of Orthopedic Surgery, Pius-Hospital , Carl-von-Ossietzky-University , Oldenburg , Germany
| | - Franz Jakob
- c Orthopedic Center for Musculoskeletal Research, Orthopedic Department , University of Wuerzburg , Wuerzburg , Germany
| | - Uwe Maus
- b Department of Orthopedic Surgery, Pius-Hospital , Carl-von-Ossietzky-University , Oldenburg , Germany
| | - Andreas Kurth
- d Bone Health Center Berlin-Brandenburg , Hospital Birkenwerder , Birkenwerder Germany
| | - Axel Jakuscheit
- a Department of Orthopedics , Koenig-Ludwig-Haus, University of Wuerzburg , Wuerzburg , Germany
| | - Maximilian Rudert
- a Department of Orthopedics , Koenig-Ludwig-Haus, University of Wuerzburg , Wuerzburg , Germany
| | - Boris Michael Holzapfel
- a Department of Orthopedics , Koenig-Ludwig-Haus, University of Wuerzburg , Wuerzburg , Germany.,e Centre for Regenerative Medicine, Institute of Health and Biomedical Innovation , Queensland University of Technology , Brisbane , Australia
| |
Collapse
|
29
|
Kanis JA, Cooper C, Rizzoli R, Abrahamsen B, Al-Daghri NM, Brandi ML, Cannata-Andia J, Cortet B, Dimai HP, Ferrari S, Hadji P, Harvey NC, Kraenzlin M, Kurth A, McCloskey E, Minisola S, Thomas T, Reginster JY. Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 2017; 28:2023-2034. [PMID: 28451733 PMCID: PMC5483332 DOI: 10.1007/s00198-017-4009-0] [Citation(s) in RCA: 99] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Accepted: 03/10/2017] [Indexed: 12/21/2022]
Abstract
Osteoporosis represents a significant and increasing healthcare burden in Europe, but most patients at increased risk of fracture do not receive medication, resulting in a large treatment gap. Identification of patients who are at particularly high risk will help clinicians target appropriate treatment more precisely and cost-effectively, and should be the focus of future research. INTRODUCTION The purpose of the study was to review data on the identification and treatment of patients with osteoporosis at increased risk of fracture. METHODS A working group convened by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis met to review current data on the epidemiology and burden of osteoporosis and the patterns of medical management throughout Europe. RESULTS In Europe in 2010, the cost of managing osteoporosis was estimated at €37 billion and notably the costs of treatment and long-term care of patients with fractures were considerably higher than the costs for pharmacological prevention. Despite the availability of effective treatments, the uptake of osteoporosis therapy is low and declining, in particular for secondary fracture prevention where the risk of a subsequent fracture following a first fracture is high. Consequently, there is a significant treatment gap between those who would benefit from treatment and those who receive it, which urgently needs to be addressed so that the burden of disease can be reduced. CONCLUSIONS Implementation of global fracture prevention strategies is a critical need. Future research should focus on identifying specific risk factors for imminent fractures, periods of high fracture risk, patients who are at increased risk of fracture and therapies that are most suited to such high-risk patients and optimal implementation strategies in primary, secondary and tertiary care.
Collapse
Affiliation(s)
- J A Kanis
- Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK.
- Institute for Health and Ageing, Catholic University of Australia, Melbourne, Australia.
| | - C Cooper
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
- NIHR Musculoskeletal Biomedical Research Unit, University of Oxford, Oxford, UK
| | - R Rizzoli
- Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - B Abrahamsen
- Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
| | - N M Al-Daghri
- Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia
| | - M L Brandi
- Department of Surgery and Translational Medicine, Unit of Bone and Mineral Diseases, University of Florence, Florence, Italy
| | - J Cannata-Andia
- Bone and Mineral Research Unit, Instituto "Reina Sofía" de Investigación, REDinREN ISCIII, Hospital Universitario Central de Asturias, Universidad de Oviedo, Asturias, Spain
| | - B Cortet
- Department of Rheumatology, Lille University Hospital, Lille, France
| | - H P Dimai
- Department of Internal Medicine, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria
| | - S Ferrari
- Service of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - P Hadji
- Department of Bone Oncology, Endocrinology and Reproductive Medicine, Krankenhaus Nordwest, Frankfurt, Germany
| | - N C Harvey
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK
| | - M Kraenzlin
- Endonet, Endocrine Clinic and Laboratory, Basel, Switzerland
| | - A Kurth
- Department of Orthopaedic Surgery and Osteology, Klinikum Frankfurt, Frankfurt, Germany
- Mayor Teaching Hospital, Charitè Medical School, Berlin, Germany
| | - E McCloskey
- Centre for Metabolic Bone Diseases, University of Sheffield Medical School, Beech Hill Road, Sheffield, S10 2RX, UK
- MRC and Arthritis Research UK Centre for Integrated Research in Musculoskeletal Ageing, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK
| | - S Minisola
- Department of Internal Medicine and Medical Disciplines, "Sapienza" Università di Roma, Rome, Italy
| | - T Thomas
- INSERM U1059, Laboratoire Biologie Intégrée du Tissu Osseux, Rheumatology Department, CHU Saint-Etienne, Université de Lyon, Saint-Etienne, France
| | - J-Y Reginster
- Department of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| |
Collapse
|
30
|
Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE. Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 2017; 7:1-12. [PMID: 28413771 PMCID: PMC5384888 DOI: 10.1016/j.jbo.2017.03.001] [Citation(s) in RCA: 149] [Impact Index Per Article: 21.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Accepted: 03/10/2017] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase inhibitor (AI) therapy. Recently, a number of studies on additional fracture related risk factors, new treatment options as well as real world studies demonstrating a much higher fracture rate than suggested by randomized clinical controlled trials (RCTs). Therefore, this updated algorithm was developed to better assess fracture risk and direct treatment as a position statement of several interdisciplinary cancer and bone societies involved in the management of AI-associated bone loss (AIBL). PATIENTS AND METHODS A systematic literature review identified recent advances in the management of AIBL. Results with individual agents were assessed based on trial design, size, follow-up, and safety. RESULTS Several fracture related risk factors in patients with EBC were identified. Although, the FRAX algorithm includes fracture risk factors (RF) in addition to BMD, it does not seem to adequately address the effects of AIBL. Several antiresorptive agents can prevent and treat AIBL. However, concerns regarding compliance and long-term safety remain. Overall, the evidence for fracture prevention is strongest for denosumab 60 mg s.c. every 6 months. Additionally, recent studies as well as an individual patient data meta-analysis of all available randomized trial data support additional anticancer benefits from adjuvant bisphosphonate treatment in postmenopausal women with a 34% relative risk reduction in bone metastasis and 17% relative risk decrease in breast cancer mortality that needs to be taken into account when advising on management of AIBL. CONCLUSIONS In all patients initiating AI treatment, fracture risk should be assessed and recommendation with regard to exercise and calcium/vitamin D supplementation given. Bone-directed therapy should be given to all patients with a T-score<-2.0 or with a T-score of <-1.5 SD with one additional RF, or with ≥2 risk factors (without BMD) for the duration of AI treatment. Patients with T-score>-1.5 SD and no risk factors should be managed based on BMD loss during the first year and the local guidelines for postmenopausal osteoporosis. Compliance should be regularly assessed as well as BMD on treatment after 12 - 24 months. Furthermore, because of the decreased incidence of bone recurrence and breast cancer specific mortality, adjuvant bisphosphonates are recommended for all postmenopausal women at significant risk of disease recurrence.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | - John Kanis
- Catholic University of Australia, Melbourne, Australia and University of Sheffield, UK
| | | | | | | | | | | | | |
Collapse
|
31
|
Kerber R, Krumkamp R, Diallo B, Jaeger A, Rudolf M, Lanini S, Bore JA, Koundouno FR, Becker-Ziaja B, Fleischmann E, Stoecker K, Meschi S, Mély S, Newman ENC, Carletti F, Portmann J, Korva M, Wolff S, Molkenthin P, Kis Z, Kelterbaum A, Bocquin A, Strecker T, Fizet A, Castilletti C, Schudt G, Ottowell L, Kurth A, Atkinson B, Badusche M, Cannas A, Pallasch E, Bosworth A, Yue C, Pályi B, Ellerbrok H, Kohl C, Oestereich L, Logue CH, Lüdtke A, Richter M, Ngabo D, Borremans B, Becker D, Gryseels S, Abdellati S, Vermoesen T, Kuisma E, Kraus A, Liedigk B, Maes P, Thom R, Duraffour S, Diederich S, Hinzmann J, Afrough B, Repits J, Mertens M, Vitoriano I, Bah A, Sachse A, Boettcher JP, Wurr S, Bockholt S, Nitsche A, Županc TA, Strasser M, Ippolito G, Becker S, Raoul H, Carroll MW, De Clerck H, Van Herp M, Sprecher A, Koivogui L, Magassouba N, Keïta S, Drury P, Gurry C, Formenty P, May J, Gabriel M, Wölfel R, Günther S, Di Caro A. Analysis of Diagnostic Findings From the European Mobile Laboratory in Guéckédou, Guinea, March 2014 Through March 2015. J Infect Dis 2016; 214:S250-S257. [PMID: 27638946 PMCID: PMC5050480 DOI: 10.1093/infdis/jiw269] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background. A unit of the European Mobile Laboratory (EMLab) consortium was deployed to the Ebola virus disease (EVD) treatment unit in Guéckédou, Guinea, from March 2014 through March 2015. Methods. The unit diagnosed EVD and malaria, using the RealStar Filovirus Screen reverse transcription–polymerase chain reaction (RT-PCR) kit and a malaria rapid diagnostic test, respectively. Results. The cleaned EMLab database comprised 4719 samples from 2741 cases of suspected EVD from Guinea. EVD was diagnosed in 1231 of 2178 hospitalized patients (57%) and in 281 of 563 who died in the community (50%). Children aged <15 years had the highest proportion of Ebola virus–malaria parasite coinfections. The case-fatality ratio was high in patients aged <5 years (80%) and those aged >74 years (90%) and low in patients aged 10–19 years (40%). On admission, RT-PCR analysis of blood specimens from patients who died in the hospital yielded a lower median cycle threshold (Ct) than analysis of blood specimens from survivors (18.1 vs 23.2). Individuals who died in the community had a median Ct of 21.5 for throat swabs. Multivariate logistic regression on 1047 data sets revealed that low Ct values, ages of <5 and ≥45 years, and, among children aged 5–14 years, malaria parasite coinfection were independent determinants of a poor EVD outcome. Conclusions. Virus load, age, and malaria parasite coinfection play a role in the outcome of EVD.
Collapse
Affiliation(s)
- Romy Kerber
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Ralf Krumkamp
- Bernhard Nocht Institute for Tropical Medicine German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | | | - Anna Jaeger
- Bernhard Nocht Institute for Tropical Medicine German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Martin Rudolf
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Simone Lanini
- European Mobile Laboratory Consortium National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| | | | | | - Beate Becker-Ziaja
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Erna Fleischmann
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Bundeswehr Institute of Microbiology, Munich
| | - Kilian Stoecker
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Bundeswehr Institute of Microbiology, Munich
| | - Silvia Meschi
- European Mobile Laboratory Consortium National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| | - Stéphane Mély
- European Mobile Laboratory Consortium National Reference Center for Viral Hemorrhagic Fevers Laboratoire P4 Inserm-Jean Mérieux
| | - Edmund N C Newman
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Fabrizio Carletti
- European Mobile Laboratory Consortium National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| | - Jasmine Portmann
- European Mobile Laboratory Consortium Spiez Laboratory, Federal Office for Civil Protection
| | - Misa Korva
- European Mobile Laboratory Consortium Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Slovenia
| | - Svenja Wolff
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Institute of Virology, Philipps University Marburg
| | - Peter Molkenthin
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Bundeswehr Institute of Microbiology, Munich
| | - Zoltan Kis
- European Mobile Laboratory Consortium National Biosafety Laboratory, National Center for Epidemiology, Budapest, Hungary
| | - Anne Kelterbaum
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Institute of Virology, Philipps University Marburg
| | - Anne Bocquin
- European Mobile Laboratory Consortium National Reference Center for Viral Hemorrhagic Fevers Laboratoire P4 Inserm-Jean Mérieux
| | - Thomas Strecker
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Institute of Virology, Philipps University Marburg
| | - Alexandra Fizet
- European Mobile Laboratory Consortium National Reference Center for Viral Hemorrhagic Fevers Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, France
| | - Concetta Castilletti
- European Mobile Laboratory Consortium National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| | - Gordian Schudt
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Institute of Virology, Philipps University Marburg
| | - Lisa Ottowell
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Andreas Kurth
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | - Barry Atkinson
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Marlis Badusche
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Angela Cannas
- European Mobile Laboratory Consortium National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| | - Elisa Pallasch
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Andrew Bosworth
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Constanze Yue
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | - Bernadett Pályi
- European Mobile Laboratory Consortium National Biosafety Laboratory, National Center for Epidemiology, Budapest, Hungary
| | - Heinz Ellerbrok
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | - Claudia Kohl
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | - Lisa Oestereich
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | | | - Anja Lüdtke
- European Mobile Laboratory Consortium Heinrich Pette Institute-Leibniz Institute for Experimental Virology, Hamburg German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Martin Richter
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | - Didier Ngabo
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Benny Borremans
- European Mobile Laboratory Consortium Evolutionary Ecology Group, Department of Biology, University of Antwerp
| | - Dirk Becker
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Institute of Virology, Philipps University Marburg
| | - Sophie Gryseels
- European Mobile Laboratory Consortium Evolutionary Ecology Group, Department of Biology, University of Antwerp
| | - Saïd Abdellati
- European Mobile Laboratory Consortium Institute of Tropical Medicine, Antwerp
| | - Tine Vermoesen
- European Mobile Laboratory Consortium Institute of Tropical Medicine, Antwerp
| | - Eeva Kuisma
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Annette Kraus
- European Mobile Laboratory Consortium Public Health Agency of Sweden, Solna
| | - Britta Liedigk
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Piet Maes
- European Mobile Laboratory Consortium Department of Microbiology and Immunology, Rega Institute, KU Leuven
| | - Ruth Thom
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Sophie Duraffour
- European Mobile Laboratory Consortium Department of Microbiology and Immunology, Rega Institute, KU Leuven
| | - Sandra Diederich
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Insel Riems, Germany
| | - Julia Hinzmann
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | - Babak Afrough
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Johanna Repits
- European Mobile Laboratory Consortium Janssen-Cilag, Stockholm, Sweden
| | - Marc Mertens
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Insel Riems, Germany
| | - Inês Vitoriano
- European Mobile Laboratory Consortium Public Health England, Porton Down
| | - Amadou Bah
- European Mobile Laboratory Consortium Swiss Tropical and Public Health Institute, Basel
| | - Andreas Sachse
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | | | - Stephanie Wurr
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Sabrina Bockholt
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Andreas Nitsche
- European Mobile Laboratory Consortium Robert Koch Institute, Berlin
| | - Tatjana Avšič Županc
- European Mobile Laboratory Consortium Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Slovenia
| | - Marc Strasser
- European Mobile Laboratory Consortium Spiez Laboratory, Federal Office for Civil Protection
| | - Giuseppe Ippolito
- European Mobile Laboratory Consortium National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| | - Stephan Becker
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Institute of Virology, Philipps University Marburg
| | - Herve Raoul
- European Mobile Laboratory Consortium Laboratoire P4 Inserm-Jean Mérieux
| | - Miles W Carroll
- European Mobile Laboratory Consortium Public Health England, Porton Down South General Hospital, University of Southampton, United Kingdom
| | | | | | | | | | - N'Faly Magassouba
- Université Gamal Abdel Nasser de Conakry, Laboratoire des Fièvres Hémorragiques en Guinée, Guinea
| | | | | | | | | | - Jürgen May
- Bernhard Nocht Institute for Tropical Medicine German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Martin Gabriel
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Roman Wölfel
- European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems Bundeswehr Institute of Microbiology, Munich
| | - Stephan Günther
- Bernhard Nocht Institute for Tropical Medicine European Mobile Laboratory Consortium German Center for Infection Research, Hamburg-Munich-Marburg-Riems
| | - Antonino Di Caro
- European Mobile Laboratory Consortium National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy
| |
Collapse
|
32
|
Spengler JR, Lavender KJ, Martellaro C, Carmody A, Kurth A, Keck JG, Saturday G, Scott DP, Nichol ST, Hasenkrug KJ, Spiropoulou CF, Feldmann H, Prescott J. Ebola Virus Replication and Disease Without Immunopathology in Mice Expressing Transgenes to Support Human Myeloid and Lymphoid Cell Engraftment. J Infect Dis 2016; 214:S308-S318. [PMID: 27601621 DOI: 10.1093/infdis/jiw248] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
The study of Ebola virus (EBOV) pathogenesis in vivo has been limited to nonhuman primate models or use of an adapted virus to cause disease in rodent models. Herein we describe wild-type EBOV (Makona variant) infection of mice engrafted with human hematopoietic CD34+ stem cells (Hu-NSG™-SGM3 mice; hereafter referred to as SGM3 HuMice). SGM3 HuMice support increased development of myeloid immune cells, which are primary EBOV targets. In SGM3 HuMice, EBOV replicated to high levels, and disease was observed following either intraperitoneal or intramuscular inoculation. Despite the high levels of viral antigen and inflammatory cell infiltration in the liver, the characteristic histopathology of Ebola virus disease was not observed, and this absence of severe immunopathology may have contributed to the recovery and survival of some of the animals. Future investigations into the underlying mechanisms of the atypical disease presentation in SGM3 HuMice will provide additional insights into the immunopathogenesis of severe EBOV disease.
Collapse
Affiliation(s)
- Jessica R Spengler
- Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | | | | - Andreas Kurth
- Center for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - James G Keck
- In Vivo Services, The Jackson Laboratory, Sacramento, California
| | - Greg Saturday
- Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana
| | - Dana P Scott
- Rocky Mountain Veterinary Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana
| | - Stuart T Nichol
- Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | - Christina F Spiropoulou
- Viral Special Pathogens Branch, Division of High Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | |
Collapse
|
33
|
Miller MR, McMinn RJ, Misra V, Schountz T, Müller MA, Kurth A, Munster VJ. Broad and Temperature Independent Replication Potential of Filoviruses on Cells Derived From Old and New World Bat Species. J Infect Dis 2016; 214:S297-S302. [PMID: 27354372 DOI: 10.1093/infdis/jiw199] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Filoviruses are strongly associated with several species of bats as their natural reservoirs. In this study, we determined the replication potential of all filovirus species: Marburg marburgvirus, Taï Forest ebolavirus, Reston ebolavirus, Sudan ebolavirus, Zaire ebolavirus, and Bundibugyo ebolavirus. Filovirus replication was supported by all cell lines derived from 6 Old and New World bat species: the hammer-headed fruit bat, Buettikofer's epauletted fruit bat, the Egyptian fruit bat, the Jamaican fruit bat, the Mexican free-tailed bat and the big brown bat. In addition, we showed that Marburg virus Angola and Ebola virus Makona-WPGC07 efficiently replicated at 37°C, 37°-41°C, or 41°C, contrary to the hypothesis that temporal elevation in temperature due to flight affects filovirus replication in bats.
Collapse
Affiliation(s)
- Megan R Miller
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana
| | - Rebekah J McMinn
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana
| | - Vikram Misra
- Department of Microbiology, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, Canada
| | - Tony Schountz
- Arthropod-borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins
| | | | - Andreas Kurth
- Biosafety Level 4 Laboratory, Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Vincent J Munster
- Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rocky Mountain Laboratories, Hamilton, Montana
| |
Collapse
|
34
|
Arias A, Watson SJ, Asogun D, Tobin EA, Lu J, Phan MVT, Jah U, Wadoum REG, Meredith L, Thorne L, Caddy S, Tarawalie A, Langat P, Dudas G, Faria NR, Dellicour S, Kamara A, Kargbo B, Kamara BO, Gevao S, Cooper D, Newport M, Horby P, Dunning J, Sahr F, Brooks T, Simpson AJH, Groppelli E, Liu G, Mulakken N, Rhodes K, Akpablie J, Yoti Z, Lamunu M, Vitto E, Otim P, Owilli C, Boateng I, Okoror L, Omomoh E, Oyakhilome J, Omiunu R, Yemisis I, Adomeh D, Ehikhiametalor S, Akhilomen P, Aire C, Kurth A, Cook N, Baumann J, Gabriel M, Wölfel R, Di Caro A, Carroll MW, Günther S, Redd J, Naidoo D, Pybus OG, Rambaut A, Kellam P, Goodfellow I, Cotten M. Rapid outbreak sequencing of Ebola virus in Sierra Leone identifies transmission chains linked to sporadic cases. Virus Evol 2016; 2:vew016. [PMID: 28694998 PMCID: PMC5499387 DOI: 10.1093/ve/vew016] [Citation(s) in RCA: 91] [Impact Index Per Article: 11.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
To end the largest known outbreak of Ebola virus disease (EVD) in West Africa and to prevent new transmissions, rapid epidemiological tracing of cases and contacts was required. The ability to quickly identify unknown sources and chains of transmission is key to ending the EVD epidemic and of even greater importance in the context of recent reports of Ebola virus (EBOV) persistence in survivors. Phylogenetic analysis of complete EBOV genomes can provide important information on the source of any new infection. A local deep sequencing facility was established at the Mateneh Ebola Treatment Centre in central Sierra Leone. The facility included all wetlab and computational resources to rapidly process EBOV diagnostic samples into full genome sequences. We produced 554 EBOV genomes from EVD cases across Sierra Leone. These genomes provided a detailed description of EBOV evolution and facilitated phylogenetic tracking of new EVD cases. Importantly, we show that linked genomic and epidemiological data can not only support contact tracing but also identify unconventional transmission chains involving body fluids, including semen. Rapid EBOV genome sequencing, when linked to epidemiological information and a comprehensive database of virus sequences across the outbreak, provided a powerful tool for public health epidemic control efforts.
Collapse
Affiliation(s)
- Armando Arias
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Simon J Watson
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Danny Asogun
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Ekaete Alice Tobin
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Jia Lu
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - My V T Phan
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Umaru Jah
- University of Makeni, Makeni, Sierra Leone
| | | | - Luke Meredith
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Lucy Thorne
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | - Sarah Caddy
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom
| | | | - Pinky Langat
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| | - Gytis Dudas
- Institute of Evolutionary Biology, Ashworth Laboratories, Edinburgh, United Kingdom
| | - Nuno R Faria
- Department of Zoology, University of Oxford, Oxford, UK
| | | | - Abdul Kamara
- Sierra Leone Ministry of Health, Freetown, Sierra Leone
| | - Brima Kargbo
- Sierra Leone Ministry of Health, Freetown, Sierra Leone
| | | | - Sahr Gevao
- Sierra Leone Ministry of Health, Freetown, Sierra Leone
| | | | | | - Peter Horby
- Department of Medicine, Epidemic Diseases Research Group Oxford (ERGO), Centre for Tropical Medicine and Global Health Nuffield, University of Oxford, Oxford, United Kingdom
| | - Jake Dunning
- Department of Medicine, Epidemic Diseases Research Group Oxford (ERGO), Centre for Tropical Medicine and Global Health Nuffield, University of Oxford, Oxford, United Kingdom
| | - Foday Sahr
- Republic of Sierra Leone Armed Forces, Freetown, Sierra Leone
| | - Tim Brooks
- Rare and Imported Pathogens Laboratory, Public Health England, United Kingdom
| | - Andrew J H Simpson
- Rare and Imported Pathogens Laboratory, Public Health England, United Kingdom
| | | | - Guoying Liu
- Thermo Fisher Scientific, South San Francisco, CA, USA
| | | | - Kate Rhodes
- Thermo Fisher Scientific, South San Francisco, CA, USA
| | | | | | | | | | | | | | | | | | - Emmanuel Omomoh
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Jennifer Oyakhilome
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Racheal Omiunu
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Ighodalo Yemisis
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Donatus Adomeh
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Solomon Ehikhiametalor
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Patience Akhilomen
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Chris Aire
- Irrua Specialist Teaching Hospital, Institute of Lassa Fever Research and Control, Irrua, Nigeria.,The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Andreas Kurth
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,Robert Koch Institute, Berlin, Germany
| | - Nicola Cook
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,Public Health England, Porton Down, United Kingdom
| | - Jan Baumann
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Martin Gabriel
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - Roman Wölfel
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,Bundeswehr Institute of Microbiology, Munich, Germany
| | - Antonino Di Caro
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy
| | - Miles W Carroll
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,Public Health England, Porton Down, United Kingdom
| | - Stephan Günther
- The European Mobile Laboratory Consortium, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.,Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany
| | - John Redd
- Sierra Leone and Division of Global Health Protection, CDC Country Office, Georgia Center for Global Health Centers for Disease Control and Prevention, Atlanta, GA, USA
| | | | | | - Andrew Rambaut
- Institute of Evolutionary Biology, Ashworth Laboratories, Edinburgh, United Kingdom.,Fogarty International Center, NIH, Bethesda, MD, USA.,Infection and Evolution, Centre for Immunology, Ashworth Laboratories, Edinburgh, United Kingdom
| | - Paul Kellam
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom.,Division of Infection and Immunity, University College London, London, United Kingdom
| | - Ian Goodfellow
- Division of Virology, Department of Pathology, University of Cambridge, Cambridge, United Kingdom.,University of Makeni, Makeni, Sierra Leone
| | - Matthew Cotten
- Wellcome Trust Sanger Institute, Hinxton, United Kingdom
| |
Collapse
|
35
|
Jehn CF, Diel IJ, Overkamp F, Kurth A, Schaefer R, Miller K, Lüftner D. Management of Metastatic Bone Disease Algorithms for Diagnostics and Treatment. Anticancer Res 2016; 36:2631-2637. [PMID: 27272771] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2016] [Accepted: 04/27/2016] [Indexed: 06/06/2023]
Abstract
BACKGROUND Bone is a frequent site of metastases in advanced cancer and is associated with significant skeletal morbidity. Current treatment options are aimed at preserving and improving functional independence and quality of life. MATERIALS AND METHODS A review of current literature focusing on diagnostic tools and treatment approaches of bone metastasis in advanced cancer was performed and conclusions were incorporated into diagnostic and treatment algorithms. RESULTS Radiologic imaging has added valuable tools for screening and diagnostics of bone metastasis. Clinical management of skeletal metastasis includes improved pain management, introduction of bone modifying agents and advancements in surgical and radiation therapy. We propose three algorithms enhancing the sensitivity of diagnostics and improving multidisciplinary management of vertebral and non-vertebral bone metastasis. CONCLUSION Bone metastases are an expression of a systemic disease. Treatment options include highly specialized modalities yet need to be tailored to individual needs. Algorithms help standardize treatment procedures and can improve treatment outcome in a multidisciplinary setting.
Collapse
Affiliation(s)
- Christian F Jehn
- Department of Hematology, Oncology and Tumor Immunology, University Hospital Charité, Berlin, Germany
| | - Ingo J Diel
- Practice for Medical Oncology and Gynaecology am Rosengarten, Mannheim, Germany
| | | | - Andreas Kurth
- THEMISTOCLES GLUCK Hospital Ratingen, Ratingen, Germany
| | | | - Kurt Miller
- Department of Urology, University Hospital Charité, Berlin, Germany
| | - Diana Lüftner
- Department of Hematology, Oncology and Tumor Immunology, University Hospital Charité, Berlin, Germany
| |
Collapse
|
36
|
Kurth A. Osteoporose/Knochenerkrankungen. Unfallchirurg 2016; 119:174-5. [DOI: 10.1007/s00113-016-0148-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
37
|
Gignoux E, Azman AS, de Smet M, Azuma P, Massaquoi M, Job D, Tiffany A, Petrucci R, Sterk E, Potet J, Suzuki M, Kurth A, Cannas A, Bocquin A, Strecker T, Logue C, Pottage T, Yue C, Cabrol JC, Serafini M, Ciglenecki I. Effect of Artesunate-Amodiaquine on Mortality Related to Ebola Virus Disease. N Engl J Med 2016; 374:23-32. [PMID: 26735991 DOI: 10.1056/nejmoa1504605] [Citation(s) in RCA: 89] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND Malaria treatment is recommended for patients with suspected Ebola virus disease (EVD) in West Africa, whether systeomatically or based on confirmed malaria diagnosis. At the Ebola treatment center in Foya, Lofa County, Liberia, the supply of artemether-lumefantrine, a first-line antimalarial combination drug, ran out for a 12-day period in August 2014. During this time, patients received the combination drug artesunate-amodiaquine; amodiaquine is a compound with anti-Ebola virus activity in vitro. No other obvious change in the care of patients occurred during this period. METHODS We fit unadjusted and adjusted regression models to standardized patient-level data to estimate the risk ratio for death among patients with confirmed EVD who were prescribed artesunate-amodiaquine (artesunate-amodiaquine group), as compared with those who were prescribed artemether-lumefantrine (artemether-lumefantrine group) and those who were not prescribed any antimalarial drug (no-antimalarial group). RESULTS Between June 5 and October 24, 2014, a total of 382 patients with confirmed EVD were admitted to the Ebola treatment center in Foya. At admission, 194 patients were prescribed artemether-lumefantrine and 71 were prescribed artesunate-amodiaquine. The characteristics of the patients in the artesunate-amodiaquine group were similar to those in the artemether-lumefantrine group and those in the no-antimalarial group. A total of 125 of the 194 patients in the artemether-lumefantrine group (64.4%) died, as compared with 36 of the 71 patients in the artesunate-amodiaquine group (50.7%). In adjusted analyses, the artesunate-amodiaquine group had a 31% lower risk of death than the artemether-lumefantrine group (risk ratio, 0.69; 95% confidence interval, 0.54 to 0.89), with a stronger effect observed among patients without malaria. CONCLUSIONS Patients who were prescribed artesunate-amodiaquine had a lower risk of death from EVD than did patients who were prescribed artemether-lumefantrine. However, our analyses cannot exclude the possibility that artemether-lumefantrine is associated with an increased risk of death or that the use of artesunate-amodiaquine was associated with unmeasured patient characteristics that directly altered the risk of death.
Collapse
Affiliation(s)
- Etienne Gignoux
- From the Epicentre (E.G., A.T.) and Médecins sans Frontières Access Campaign (J.P.), Paris, and Laboratoire P4 Jean Merieux, INSERM, Lyon (A.B.) - all in France; Médecins sans Frontières, Geneva (E.G., A.S.A., D.J., A.T., R.P., E.S., M. Suzuki, J.-C.C., M. Serafini, I.C.); the Department of Epidemiology, Johns Hopkins University, Baltimore (A.S.A.); Médecins sans Frontières, Brussels (M. de Smet); Ministry of Health and Social Welfare, Monrovia, Liberia (P.A., M.M.); the Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan (M. Suzuki); European Mobile Laboratory Consortium, Hamburg (A.K., A.C., A.B., T.S., C.L., T.P., C.Y.), Robert Koch Institute, Berlin (A.K., C.Y.), and the Institute of Virology, Philipps-University Marburg, Marburg (T.S.) - all in Germany; Istituto Nazionale per le Malattie Infettive L. Spallanzani, Rome (A.C.); and Public Health England, Porton Down, United Kingdom (C.L., T.P.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
38
|
Caluwaerts S, Fautsch T, Lagrou D, Moreau M, Modet Camara A, Günther S, Di Caro A, Borremans B, Raymond Koundouno F, Akoi Bore J, Logue CH, Richter M, Wölfel R, Kuisma E, Kurth A, Thomas S, Burkhardt G, Erland E, Lionetto F, Lledo Weber P, de la Rosa O, Macpherson H, Van Herp M. Dilemmas in Managing Pregnant Women With Ebola: 2 Case Reports. Clin Infect Dis 2015; 62:903-905. [PMID: 26679622 PMCID: PMC4787604 DOI: 10.1093/cid/civ1024] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 12/09/2015] [Indexed: 11/20/2022] Open
Abstract
We report 2 cases of Ebola viral disease (EVD) in pregnant women who survived, initially with intact pregnancies. Respectively 31–32 days after negativation of the maternal blood EVD-polymerase chain reaction (PCR) both patients delivered a stillborn fetus with persistent EVD-PCR amniotic fluid positivity.
Collapse
Affiliation(s)
- Séverine Caluwaerts
- Médecins Sans Frontières, Operational Centre Brussels.,Institute of Tropical Medicine, Antwerp
| | - Tessy Fautsch
- Médecins Sans Frontières, Operational Centre Brussels
| | - Daphne Lagrou
- Médecins Sans Frontières, Operational Centre Brussels
| | - Michel Moreau
- Department of Emergency Medicine, Centre Hospitalier Chrétien, Liège, Belgium
| | | | - Stephan Günther
- The European Mobile Laboratory Consortium.,Bernhard Nocht Institute for Tropical Medicine, World Health Organization Collaborating Centre for Arboviruses and Hemorrhagic Fever Reference and Research, Hamburg, Germany
| | - Antonino Di Caro
- The European Mobile Laboratory Consortium.,National Institute for Infectious Diseases "L. Spallanzani", Rome, Italy
| | - Benny Borremans
- The European Mobile Laboratory Consortium.,Evolutionary Ecology Group, University of Antwerp, Belgium
| | - Fara Raymond Koundouno
- The European Mobile Laboratory Consortium.,Laboratoire des Fièvres Hémorragiques en Guinée, Université Gamal Abdel Nasser de Conakry.,Institut National de Santé Publique, Conakry, Guinea
| | - Joseph Akoi Bore
- The European Mobile Laboratory Consortium.,Laboratoire des Fièvres Hémorragiques en Guinée, Université Gamal Abdel Nasser de Conakry.,Institut National de Santé Publique, Conakry, Guinea
| | - Christopher H Logue
- The European Mobile Laboratory Consortium.,Public Health England, Porton Down, United Kingdom
| | - Martin Richter
- The European Mobile Laboratory Consortium.,Robert Koch Institute, Berlin
| | - Roman Wölfel
- The European Mobile Laboratory Consortium.,Bundeswehr Institute of Microbiology, Munich, Germany
| | - Eeva Kuisma
- The European Mobile Laboratory Consortium.,Public Health England, Porton Down, United Kingdom
| | - Andreas Kurth
- The European Mobile Laboratory Consortium.,Robert Koch Institute, Berlin
| | - Stephen Thomas
- The European Mobile Laboratory Consortium.,Public Health England, Porton Down, United Kingdom
| | | | - Elin Erland
- Médecins Sans Frontières, Operational Centre Barcelona, Spain
| | | | | | | | | | | |
Collapse
|
39
|
Vidovszky MZ, Kohl C, Boldogh S, Görföl T, Wibbelt G, Kurth A, Harrach B. Random sampling of the Central European bat fauna reveals the existence of numerous hitherto unknown adenoviruses. Acta Vet Hung 2015; 63:508-25. [PMID: 26599097 DOI: 10.1556/004.2015.047] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
From over 1250 extant species of the order Chiroptera, 25 and 28 are known to occur in Germany and Hungary, respectively. Close to 350 samples originating from 28 bat species (17 from Germany, 27 from Hungary) were screened for the presence of adenoviruses (AdVs) using a nested PCR that targets the DNA polymerase gene of AdVs. An additional PCR was designed and applied to amplify a fragment from the gene encoding the IVa2 protein of mastadenoviruses. All German samples originated from organs of bats found moribund or dead. The Hungarian samples were excrements collected from colonies of known bat species, throat or rectal swab samples, taken from live individuals that had been captured for faunistic surveys and migration studies, as well as internal organs of dead specimens. Overall, 51 samples (14.73%) were found positive. We detected 28 seemingly novel and six previously described bat AdVs by sequencing the PCR products. The positivity rate was the highest among the guano samples of bat colonies. In phylogeny reconstructions, the AdVs detected in bats clustered roughly, but not perfectly, according to the hosts' families (Vespertilionidae, Rhinolophidae, Hipposideridae, Phyllostomidae and Pteropodidae). In a few cases, identical sequences were derived from animals of closely related species. On the other hand, some bat species proved to harbour more than one type of AdV. The high prevalence of infection and the large number of chiropteran species worldwide make us hypothesise that hundreds of different yet unknown AdV types might circulate in bats.
Collapse
Affiliation(s)
- Márton Z. Vidovszky
- 1Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, H-1143 Budapest, Hungary
| | - Claudia Kohl
- 2Robert Koch Institute, Centre for Biological Threats and Special Pathogens, Berlin, Germany
| | | | - Tamás Görföl
- 1Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, H-1143 Budapest, Hungary
- 4Department of Zoology, Hungarian Natural History Museum, Budapest, Hungary
| | - Gudrun Wibbelt
- 5 Leibniz Institute for Zoo and Wildlife Research, Berlin, Germany
| | - Andreas Kurth
- 2Robert Koch Institute, Centre for Biological Threats and Special Pathogens, Berlin, Germany
| | - Balázs Harrach
- 1Institute for Veterinary Medical Research, Centre for Agricultural Research, Hungarian Academy of Sciences, Hungária krt. 21, H-1143 Budapest, Hungary
| |
Collapse
|
40
|
Hing H, Muranaka Y, Kurth A, Gelderbloms H, Sahalan A, Kaswandi M, Hyatt A. C2-O-03Importance of Rapid Diagnostic Electron Microscopy in Emerging Infectious Diseases. Microscopy (Oxf) 2015. [DOI: 10.1093/jmicro/dfv185] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Abstract
This protocol can rapidly and reliably detect viruses during disease outbreaks and for detection studies. Sixty percent of emerging viruses have a zoonotic origin, making transmission from animals a major threat to public health. Prompt identification and analysis of these pathogens are indispensable to taking action toward prevention and protection of the affected population. We quantifiably compared classical and modern approaches of virus purification and enrichment in theory and experiments. Eventually, we established an unbiased protocol for detection of known and novel emerging viruses from organ tissues (tissue-based universal virus detection for viral metagenomics [TUViD-VM]). The final TUViD-VM protocol was extensively validated by using real-time PCR and next-generation sequencing. We could increase the amount of detectable virus nucleic acids and improved the detection of viruses <75,000-fold compared with other tested approaches. This TUViD-VM protocol can be used in metagenomic and virome studies to increase the likelihood of detecting viruses from any biological source.
Collapse
|
42
|
Roth A, Kurth A, Böcker W. [Osteology: the bone in focus]. Orthopade 2015; 44:661. [PMID: 26245630 DOI: 10.1007/s00132-015-3137-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- A Roth
- Klinik und Poliklinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie Bereich Endoprothetik/Orthopädie, Universitätsklinik Leipzig AöR, Liebigstraße 20, 04103, Leipzig, Deutschland.
| | - A Kurth
- Themistocles Gluck Hospital, Fachklinik für Gelenk- Wirbelsäulen- und Knochenerkrankungen, Ratingen, Deutschland
| | - W Böcker
- Klinikum der Universität München, Klinik für Allgemeine, Unfall-, Hand- und Plastische Chirurgie, München, Deutschland
| |
Collapse
|
43
|
Carroll MW, Matthews DA, Hiscox JA, Elmore MJ, Pollakis G, Rambaut A, Hewson R, García-Dorival I, Bore JA, Koundouno R, Abdellati S, Afrough B, Aiyepada J, Akhilomen P, Asogun D, Atkinson B, Badusche M, Bah A, Bate S, Baumann J, Becker D, Becker-Ziaja B, Bocquin A, Borremans B, Bosworth A, Boettcher JP, Cannas A, Carletti F, Castilletti C, Clark S, Colavita F, Diederich S, Donatus A, Duraffour S, Ehichioya D, Ellerbrok H, Fernandez-Garcia MD, Fizet A, Fleischmann E, Gryseels S, Hermelink A, Hinzmann J, Hopf-Guevara U, Ighodalo Y, Jameson L, Kelterbaum A, Kis Z, Kloth S, Kohl C, Korva M, Kraus A, Kuisma E, Kurth A, Liedigk B, Logue CH, Lüdtke A, Maes P, McCowen J, Mély S, Mertens M, Meschi S, Meyer B, Michel J, Molkenthin P, Muñoz-Fontela C, Muth D, Newman ENC, Ngabo D, Oestereich L, Okosun J, Olokor T, Omiunu R, Omomoh E, Pallasch E, Pályi B, Portmann J, Pottage T, Pratt C, Priesnitz S, Quartu S, Rappe J, Repits J, Richter M, Rudolf M, Sachse A, Schmidt KM, Schudt G, Strecker T, Thom R, Thomas S, Tobin E, Tolley H, Trautner J, Vermoesen T, Vitoriano I, Wagner M, Wolff S, Yue C, Capobianchi MR, Kretschmer B, Hall Y, Kenny JG, Rickett NY, Dudas G, Coltart CEM, Kerber R, Steer D, Wright C, Senyah F, Keita S, Drury P, Diallo B, de Clerck H, Van Herp M, Sprecher A, Traore A, Diakite M, Konde MK, Koivogui L, Magassouba N, Avšič-Županc T, Nitsche A, Strasser M, Ippolito G, Becker S, Stoecker K, Gabriel M, Raoul H, Di Caro A, Wölfel R, Formenty P, Günther S. Temporal and spatial analysis of the 2014-2015 Ebola virus outbreak in West Africa. Nature 2015; 524:97-101. [PMID: 26083749 PMCID: PMC10601607 DOI: 10.1038/nature14594] [Citation(s) in RCA: 216] [Impact Index Per Article: 24.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2015] [Accepted: 06/01/2015] [Indexed: 01/17/2023]
Abstract
West Africa is currently witnessing the most extensive Ebola virus (EBOV) outbreak so far recorded. Until now, there have been 27,013 reported cases and 11,134 deaths. The origin of the virus is thought to have been a zoonotic transmission from a bat to a two-year-old boy in December 2013 (ref. 2). From this index case the virus was spread by human-to-human contact throughout Guinea, Sierra Leone and Liberia. However, the origin of the particular virus in each country and time of transmission is not known and currently relies on epidemiological analysis, which may be unreliable owing to the difficulties of obtaining patient information. Here we trace the genetic evolution of EBOV in the current outbreak that has resulted in multiple lineages. Deep sequencing of 179 patient samples processed by the European Mobile Laboratory, the first diagnostics unit to be deployed to the epicentre of the outbreak in Guinea, reveals an epidemiological and evolutionary history of the epidemic from March 2014 to January 2015. Analysis of EBOV genome evolution has also benefited from a similar sequencing effort of patient samples from Sierra Leone. Our results confirm that the EBOV from Guinea moved into Sierra Leone, most likely in April or early May. The viruses of the Guinea/Sierra Leone lineage mixed around June/July 2014. Viral sequences covering August, September and October 2014 indicate that this lineage evolved independently within Guinea. These data can be used in conjunction with epidemiological information to test retrospectively the effectiveness of control measures, and provides an unprecedented window into the evolution of an ongoing viral haemorrhagic fever outbreak.
Collapse
Affiliation(s)
- Miles W. Carroll
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- University of Southampton, South General Hospital, Southampton, SO16 6YD UK
| | - David A. Matthews
- Department of Cellular and Molecular Medicine, School of Medical Sciences, University of Bristol, Bristol, BS8 1TD UK
| | - Julian A. Hiscox
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | | | - Georgios Pollakis
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Andrew Rambaut
- Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, EH9 2FL UK
- Fogarty International Center, National Institutes of Health, Bethesda, 20892 Maryland USA
- Centre for Immunology, Infection and Evolution, University of Edinburgh, Edinburgh, EH9 2FL UK
| | - Roger Hewson
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- London School of Hygiene and Tropical Medicine, Keppel Street, London, WC1E 7HT UK
| | - Isabel García-Dorival
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Joseph Akoi Bore
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Université Gamal Abdel Nasser de Conakry, Laboratoire des Fièvres Hémorragiques en Guinée, Conakry, Guinea
- Institut National de Santé Publique, Conakry, Guinea
| | - Raymond Koundouno
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Université Gamal Abdel Nasser de Conakry, Laboratoire des Fièvres Hémorragiques en Guinée, Conakry, Guinea
- Institut National de Santé Publique, Conakry, Guinea
| | - Saïd Abdellati
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Tropical Medicine, Antwerp, B-2000 Belgium
| | - Babak Afrough
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - John Aiyepada
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Patience Akhilomen
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Danny Asogun
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Barry Atkinson
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Marlis Badusche
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Amadou Bah
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Swiss Tropical and Public Health Institute, University of Basel, Basel, CH-4002 Switzerland
| | - Simon Bate
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Jan Baumann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Dirk Becker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Beate Becker-Ziaja
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Anne Bocquin
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, 69365 France
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, 69365 France
| | - Benny Borremans
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Department of Biology, University of Antwerp, Antwerp, B-2020 Belgium
| | - Andrew Bosworth
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Jan Peter Boettcher
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Angela Cannas
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Fabrizio Carletti
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Concetta Castilletti
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Simon Clark
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Francesca Colavita
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Sandra Diederich
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Friedrich Loeffler Institute, Federal Research Institute for Animal Health, Greifswald, 17493 Insel Riems Germany
| | - Adomeh Donatus
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Sophie Duraffour
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- KU Leuven Rega institute, Leuven, B-3000 Belgium
| | - Deborah Ehichioya
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Redeemer’s University, Osun State Nigeria
| | - Heinz Ellerbrok
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Maria Dolores Fernandez-Garcia
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Centro Nacional de Microbiologia, Instituto de Salud Carlos III, Madrid, 28029 Spain
| | - Alexandra Fizet
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, 69365 France
- Unité de Biologie des Infections Virales Emergentes, Institut Pasteur, Lyon, 69365 France
| | - Erna Fleischmann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - Sophie Gryseels
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Department of Biology, University of Antwerp, Antwerp, B-2020 Belgium
| | - Antje Hermelink
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Julia Hinzmann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Ute Hopf-Guevara
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Yemisi Ighodalo
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Lisa Jameson
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Anne Kelterbaum
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Zoltan Kis
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Center for Epidemiology, National Biosafety Laboratory, Budapest, H-1097 Hungary
| | - Stefan Kloth
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Claudia Kohl
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Miša Korva
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, SI-1000 Slovenia
| | - Annette Kraus
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Public Health Agency of Sweden, Solna, 171 82 Sweden
| | - Eeva Kuisma
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Andreas Kurth
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Britta Liedigk
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Christopher H. Logue
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Anja Lüdtke
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Heinrich Pette Institute – Leibniz Institute for Experimental Virology, Hamburg, 20251 Germany
| | - Piet Maes
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- KU Leuven Rega institute, Leuven, B-3000 Belgium
| | - James McCowen
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Stéphane Mély
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Reference Center for Viral Hemorrhagic Fevers, Lyon, 69365 France
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, 69365 France
| | - Marc Mertens
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Friedrich Loeffler Institute, Federal Research Institute for Animal Health, Greifswald, 17493 Insel Riems Germany
| | - Silvia Meschi
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Benjamin Meyer
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, University of Bonn, Bonn, 53127 Germany
| | - Janine Michel
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Peter Molkenthin
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - César Muñoz-Fontela
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Heinrich Pette Institute – Leibniz Institute for Experimental Virology, Hamburg, 20251 Germany
| | - Doreen Muth
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, University of Bonn, Bonn, 53127 Germany
| | - Edmund N. C. Newman
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Didier Ngabo
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Lisa Oestereich
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Jennifer Okosun
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Thomas Olokor
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Racheal Omiunu
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Emmanuel Omomoh
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Elisa Pallasch
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Bernadett Pályi
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Center for Epidemiology, National Biosafety Laboratory, Budapest, H-1097 Hungary
| | - Jasmine Portmann
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Federal Office for Civil Protection, Spiez Laboratory, Spiez, CH-3700 Switzerland
| | - Thomas Pottage
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Catherine Pratt
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Simone Priesnitz
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bundeswehr Hospital, Hamburg, 22049 Germany
| | - Serena Quartu
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Julie Rappe
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Virology and Immunology, Mittelhäusern, CH-3147 Switzerland
| | - Johanna Repits
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Janssen-Cilag, Sollentuna, SE-192 07 Sweden
| | - Martin Richter
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Martin Rudolf
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Andreas Sachse
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Kristina Maria Schmidt
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Gordian Schudt
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Thomas Strecker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Ruth Thom
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Stephen Thomas
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Ekaete Tobin
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Lassa Fever Research and Control, Irrua Specialist Teaching Hospital, Irrua, Edo State Nigeria
| | - Howard Tolley
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Jochen Trautner
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Thünen Institute, Hamburg, D-22767 Germany
| | - Tine Vermoesen
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Tropical Medicine, Antwerp, B-2000 Belgium
| | - Inês Vitoriano
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
| | - Matthias Wagner
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - Svenja Wolff
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Constanze Yue
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Maria Rosaria Capobianchi
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Birte Kretschmer
- Eurice - European Research and Project Office GmbH, Berlin, 10115 Germany
| | - Yper Hall
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
| | - John G. Kenny
- Centre for Genomic Research, Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB UK
| | - Natasha Y. Rickett
- Institute of Infection and Global Health, University of Liverpool, Liverpool, L69 2BE UK
| | - Gytis Dudas
- Institute of Evolutionary Biology, University of Edinburgh, Edinburgh, EH9 2FL UK
| | - Cordelia E. M. Coltart
- Department of Infection and Population Health, University College London, London, WC1E 6JB UK
| | - Romy Kerber
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Damien Steer
- Research IT, University of Bristol, Bristol, BS8 1HH UK
| | - Callum Wright
- Advanced Computing Research Centre, University of Bristol, Bristol, BS8 1HH UK
| | - Francis Senyah
- Public Health England, Porton Down, SP4 0JG Wiltshire UK
| | | | - Patrick Drury
- World Health Organization, Geneva 27, 1211 Switzerland
| | | | | | | | | | - Alexis Traore
- Section Prévention et Lutte contre la Maladie à la Direction Préfectorale de la Santé de Guéckédou, Guéckédou, Guinea
| | - Mandiou Diakite
- Université Gamal Abdel Nasser de Conakry, CHU Donka, Conakry, Guinea
| | | | | | - N’Faly Magassouba
- Université Gamal Abdel Nasser de Conakry, Laboratoire des Fièvres Hémorragiques en Guinée, Conakry, Guinea
| | - Tatjana Avšič-Županc
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Institute of Microbiology and Immunology, Faculty of Medicine, University of Ljubljana, Ljubljana, SI-1000 Slovenia
| | - Andreas Nitsche
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Robert Koch Institute, Berlin, 13353 Germany
| | - Marc Strasser
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Federal Office for Civil Protection, Spiez Laboratory, Spiez, CH-3700 Switzerland
| | - Giuseppe Ippolito
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Stephan Becker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Institute of Virology, Philipps University Marburg, Marburg, 35043 Germany
| | - Kilian Stoecker
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | - Martin Gabriel
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| | - Hervé Raoul
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Laboratoire P4 Inserm-Jean Mérieux, US003 Inserm, Lyon, 69365 France
| | - Antonino Di Caro
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- National Institute for Infectious Diseases (INMI) Lazzaro Spallanzani, Rome, 00149 Italy
| | - Roman Wölfel
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
- Bundeswehr Institute of Microbiology, Munich, 80937 Germany
| | | | - Stephan Günther
- The European Mobile Laboratory Consortium, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, D-20359 Germany
- Bernhard Nocht Institute for Tropical Medicine, Hamburg, D-20359 Germany
- German Centre for Infection Research (DZIF), Braunschweig, 38124 Germany
| |
Collapse
|
44
|
Kurth A. [Not Available]. Orthopade 2015; 44:647-648. [PMID: 26242917 DOI: 10.1007/s00132-015-3131-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]
Affiliation(s)
- A Kurth
- THEMISTOCLES GLUCK hospital, Fachklinik für Gelenk-, Wirbelsäulen- und Knochenerkrankungen, Rosenstraße 2, 40882, Ratingen, Deutschland,
| |
Collapse
|
45
|
Abstract
BACKGROUND Improvement of implant healing in orthopedic and trauma surgery serves to improve the life expectancy of the implant. Good primary stability by clamping is a prerequisite for secondary stability and for the actual integration and healing of the implant. RESULTS Possible causes of implant loosening are abrasive particles, which arrive at non-integrated implants at the unsealed prosthesis-bone interface and provoke a macrophage-mediated foreign body reaction, resulting in periprosthetic osteolysis. Numerous animal studies have already described the use of bisphosphonates to inhibit osteolysis induced by abrasion and secondary instability. In patients with total knee arthroplasty, a decrease in prosthetic migration under the influence of bisphosphonates could be shown. The stimulation of bone formation around the implants and the resulting implant healing was demonstrated both in animal experiments for bone morphogenetic proteins (BMP) and in case reports for intermittent parathyroid hormone administration. CONCLUSION By using supportive drugs, it is possible to achieve an improvement in the osseointegration of implants; thus, more rapid secondary stability and load-bearing are expected.
Collapse
Affiliation(s)
- R Skripitz
- Orthopädische Klinik und Poliklinik, Universitätsmedizin Rostock, Doberaner Str. 142, 18057, Rostock, Deutschland.
| | - A Kurth
- Themistocles Gluck Hospital, Ratingen, Deutschland
| | - A Roth
- Bereich Endoprothetik/Orthopädie, Klinik für Orthopädie, Unfallchirurgie und Plastische Chirurgie, Universitätsklinik Leipzig AöR, Leipzig, Deutschland
| |
Collapse
|
46
|
Kobak L, Raftery MJ, Voigt S, Kühl AA, Kilic E, Kurth A, Witkowski P, Hofmann J, Nitsche A, Schaade L, Krüger DH, Schönrich G. Hantavirus-induced pathogenesis in mice with a humanized immune system. J Gen Virol 2015; 96:1258-1263. [PMID: 25678530 DOI: 10.1099/vir.0.000087] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2014] [Accepted: 02/04/2015] [Indexed: 12/23/2022] Open
Abstract
Hantaviruses are emerging zoonotic pathogens that can cause severe disease in humans. Clinical observations suggest that human immune components contribute to hantavirus-induced pathology. To address this issue we generated mice with a humanized immune system. Hantavirus infection of these animals resulted in systemic infection associated with weight loss, decreased activity, ruffled fur and inflammatory infiltrates of lung tissue. Intriguingly, after infection, humanized mice harbouring human leukocyte antigen (HLA) class I-restricted human CD8+ T cells started to lose weight earlier (day 10) than HLA class I-negative humanized mice (day 15). Moreover, in these mice the number of human platelets dropped by 77 % whereas the number of murine platelets did not change, illustrating how differences between rodent and human haemato-lymphoid systems may contribute to disease development. To our knowledge this is the first description of a humanized mouse model of hantavirus infection, and our results indicate a role for human immune cells in hantaviral pathogenesis.
Collapse
Affiliation(s)
- Lidija Kobak
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Martin J Raftery
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Sebastian Voigt
- Department of Pediatric Oncology and Hematology, Charité-Universitätsmedizin Berlin, Berlin, Germany
- Division of Viral Infections, Robert Koch Institute, Berlin, Germany
| | - Anja A Kühl
- Department of Medicine I for Gastroenterology, Infectious Disease and Rheumatology/RCIS, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Ergin Kilic
- Institute of Pathology, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Kurth
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Peter Witkowski
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Jörg Hofmann
- Division of Virology, Labor Berlin Charité-Vivantes GmbH, Berlin, Germany
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Andreas Nitsche
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Lars Schaade
- Centre for Biological Threats and Special Pathogens, Robert Koch Institute, Berlin, Germany
| | - Detlev H Krüger
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Günther Schönrich
- Institute of Medical Virology, Helmut-Ruska-Haus, Charité-Universitätsmedizin Berlin, Berlin, Germany
| |
Collapse
|
47
|
Radonić A, Metzger S, Dabrowski PW, Couacy-Hymann E, Schuenadel L, Kurth A, Mätz-Rensing K, Boesch C, Leendertz FH, Nitsche A. Fatal monkeypox in wild-living sooty mangabey, Côte d'Ivoire, 2012. Emerg Infect Dis 2015. [PMID: 24857667 PMCID: PMC4036778 DOI: 10.3201/eid2006.131329] [Citation(s) in RCA: 82] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
We isolated a monkeypox virus from a wild-living monkey, a sooty mangabey, found dead in Taï National Park, Côte d'Ivoire, in March 2012. The whole-genome sequence obtained from this isolate and directly from clinical specimens showed its close relationship to monkeypox viruses from Western Africa.
Collapse
|
48
|
Abstract
Cowpox in humans is a rare zoonotic disease; its recognition is therefore problematic due to the lack of clinical experience. The differential diagnosis includes other poxvirus infections and also infections with herpesviruses or selected bacteria. The clinical course can be complicated and the improvement may take weeks. Late diagnosis is one of the causes of unnecessary combined antibiotic therapy or surgical intervention. A case of cowpox after a cat scratch in a 15-year-old girl is presented, with a summary of the available clinical data on cowpox infections.
Collapse
Affiliation(s)
- Karolina Świtaj
- Department of Zoonotic and Tropical Diseases, Medical University of Warsaw, Poland
| | - Piotr Kajfasz
- Department of Zoonotic and Tropical Diseases, Medical University of Warsaw, Poland
| | - Andreas Kurth
- Robert Koch Institute, Center for Biological Threats and Special Pathogens, Highly Pathogenic Viruses, Berlin, Germany
| | - Andreas Nitsche
- Robert Koch Institute, Center for Biological Threats and Special Pathogens, Highly Pathogenic Viruses, Berlin, Germany
| |
Collapse
|
49
|
Baggi FM, Taybi A, Kurth A, Van Herp M, Di Caro A, Wölfel R, Günther S, Decroo T, Declerck H, Jonckheere S. Management of pregnant women infected with Ebola virus in a treatment centre in Guinea, June 2014. ACTA ACUST UNITED AC 2014; 19. [PMID: 25523968 DOI: 10.2807/1560-7917.es2014.19.49.20983] [Citation(s) in RCA: 72] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
We report two cases of confirmed Ebola virus disease in pregnant women, who presented at the Médecins Sans Frontières Ebola treatment centre in Guéckédou. Despite the very high risk of death, both pregnant women survived. In both cases the critical decision was made to induce vaginal delivery. We raise a number of considerations regarding the management of Ebola virus-infected pregnant women, including the place of amniocentesis and induced delivery, and whether certain invasive medical acts are justified.
Collapse
Affiliation(s)
- F M Baggi
- Medecins Sans Frontieres - Operational Centre Brussels, Gueckedou, Guinea
| | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P. Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int 2014; 25:2721-8. [PMID: 25011986 DOI: 10.1007/s00198-014-2810-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/08/2014] [Accepted: 07/02/2014] [Indexed: 11/26/2022]
Abstract
UNLABELLED This analysis investigated the persistence of teriparatide for treatment of osteoporosis in 829 patients according to gender and health care provider treated with teriparatide. This study showed that female patients were less persistent than males and those patients treated in the practices of orthopedic surgeons were more treatment persistent than patients treated in general practitioner (GP) practices. INTRODUCTION The optimal persistency of teriparatide (TPTD) is of the upmost importance to ensure fracture risk reduction and pain relief. Data reporting on gender-specific or health care provider-dependent differences on health care provider-dependent persistence is currently lacking. METHODS We analyzed a large dataset extracted from the Disease Analyzer database (IMS Health, Germany). Out of a dataset of 15 million patients, we identified patients with osteoporosis who received first-time teriparatide prescriptions from January 2005 to December 2012. RESULTS All 829 patients (677 females and 152 males) were included in the study. The patients were treated by 214 general practitioners (GPs) and 143 orthopedic surgeons. After 18 months of follow-up, 39.5 % of the female and 34 % of the male patients discontinued their treatment (p = 0.0308). We found a significant difference in the discontinuation rate of patients treated by orthopedic surgeons (35.0 %) compared to patients treated by GPs (44.2 %) (p = 0.0445). Additionally, at the end of the 18 months of follow up, 39.4 % of female and 47.8 % of male patients were still on treatment. We found a highly significant decreased risk for treatment discontinuation in patients with fractures prior to treatment initiation compared to those without such fractures (hazard ratio (HR) 0.77; 95 % confidence interval (CI) 0.66-0.90). There was a significantly increased risk of treatment discontinuation for female patients (HR 1.38; 95 % CI 1.10-1.74) compared to male patients. CONCLUSIONS In conclusion, female patients presented higher discontinuation rates of TPTD compared to males. Patients treated in the practices of orthopedic surgeons were more persistent than patients treated in GP practices. TPTD persistence in patients with osteoporosis is higher than with antiresorptives but is still suboptimal and needs to be improved to ensure fracture risk reductions comparable to randomized controlled trial (RCT) results.
Collapse
Affiliation(s)
- I Kyvernitakis
- Department of Endocrinology, Reproductive Medicine and Osteoporosis, Philipps-University of Marburg, Baldingerstr. 1, 35043, Marburg, Germany,
| | | | | | | | | |
Collapse
|